

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00, 31/495, 31/50, 31/535, A01N 43/58, 43/60, C07D 415/00, 417/00, 403/00, 241/04, 295/00	A1	(11) International Publication Number: WO 95/34311 (43) International Publication Date: 21 December 1995 (21.12.95)
(21) International Application Number: PCT/US95/07001 (22) International Filing Date: 9 June 1995 (09.06.95) (30) Priority Data: 258,644 13 June 1994 (13.06.94) US (60) Parent Application or Grant (63) Related by Continuation US 258,644 (CON) Filed on 13 June 1994 (13.06.94) (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): NARGUND, Ravi [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BARAKAT, Khaled, J. [JO/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). CHEN, Meng, Hsin [-/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). PATCHETT, Arthur, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(74) Common Representative: MERCK & CO., INC.; Patent Dept., 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published With international search report.
(54) Title: PIPERAZINE COMPOUNDS PROMOTE RELEASE OF GROWTH HORMONE (57) Abstract Novel piperazine compounds promote the release of growth hormone in humans and animals. This property may be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such piperazine compounds as the active ingredient thereof are also disclosed.		

- 1 -

TITLE OF THE INVENTION

PIPERAZINE COMPOUNDS PROMOTE RELEASE OF GROWTH HORMONE

5 CROSS REFERENCE TO RELATED APPLICATIONS

None

BACKGROUND OF THE INVENTION

10 Growth hormone, which is secreted from the pituitary, stimulates growth of all tissues of the body that are capable of growing. In addition, growth hormone is known to have the following basic effects on the metabolic processes of the body:

1. Increased rate of protein synthesis in all cells of the body,
- 15 2. Decreased rate of carbohydrate utilization in cells of the body;
3. Increased mobilization of free fatty acids and use of fatty acids for energy.

20 A deficiency in growth hormone secretion can result in various medical disorders, such as dwarfism.

Various ways are known to release growth hormone. For example, chemicals such as arginine, L-3,4-dihydroxyphenylalanine (L-DOPA), glucagon, vasopressin, and insulin induced hypoglycemia, as well as activities such as sleep and exercise, indirectly cause growth hormone to be released from the pituitary by acting in some fashion on the hypothalamus perhaps either to decrease somatostatin secretion or to increase the secretion of the known secretagogue growth hormone releasing factor (GRF) or an unknown endogenous growth hormone-releasing hormone or all of these.

30 In cases where increased levels of growth hormone were desired, the problem was generally solved by providing exogenous growth hormone or by administering GRF or a peptidal compound which stimulated growth hormone production and/or release. In either case the peptidyl nature of the compound necessitated that it be administered by injection. Initially the source of growth hormone was

- 2 -

the extraction of the pituitary glands of cadavers. This resulted in a very expensive product and carried with it the risk that a disease associated with the source of the pituitary gland could be transmitted to the recipient of the growth hormone. Recently, recombinant growth hormone has become available which, while no longer carrying any risk of disease transmission, is still a very expensive product which must be given by injection or by a nasal spray.

Other compounds have been developed which stimulate the release of endogenous growth hormone such as analogous peptidyl compounds related to GRF or the peptides of U.S. Patent 4,411,890. These peptides, while considerably smaller than growth hormones are still susceptible to various proteases. As with most peptides, their potential for oral bioavailability is low. Non peptidal growth hormone secretagogues with a benzo-lactam structure are disclosed in U.S. Patent 4,206,235. The instant compounds are low molecular weight non-peptide analogs for promoting the release of growth hormone which have good stability in a variety of physiological environments and which may be administered parenterally, nasally or by the oral route.

SUMMARY OF THE INVENTION


The instant invention covers certain piperazine compounds which have the ability to stimulate the release of natural or endogenous growth hormone. The compounds thus have the ability to be used to treat conditions which require the stimulation of growth hormone production or secretion such as in humans with a deficiency of natural growth hormone or in animals used for food production where the stimulation of growth hormone will result in a larger, more productive animal. Thus, it is an object of the instant invention to describe the piperazine compounds. It is a further object of this invention to describe procedures for the preparation of such compounds. A still further object is to describe the use of such compounds to increase the secretion of growth hormone in humans and animals. A still further object of this invention is to describe

- 3 -

compositions containing the piperazine compounds for the use of treating humans and animals so as to increase the level of growth hormone secretions. Further objects will become apparent from a reading of the following description.

DESCRIPTION OF THE INVENTION

The novel piperazine compounds of the instant invention are best described in the following structural formula I:



wherein:

20 R₁ is selected from the group consisting of:

C₁-C₁₀ alkyl-, aryl-, aryl(C₁-C₆ alkyl)-,

heteroaryl-, heteroaryl(C₁-C₆ alkyl)-,

(C₃-C₇ cycloalkyl)-(C₁-C₆ alkyl) -,

25 (C₁-C₅ alkyl)-K-(C₁-C₅ alkyl)-,

aryl-(C₀-C₅ alkyl)-K-(C₁-C₅ alkyl)-,

heteroaryl-(C₀-C₅ alkyl)-K-(C₁-C₅ alkyl)-, and

(C₃-C₇ cycloalkyl)-(C₀-C₅ alkyl)-K-(C₁-C₅ alkyl) -,

wherein K is -O-, -S(O)_m-, -N(R₂)C(O)-, -C(O)N(R₂)-, -OC(O)-,

30 -C(O)O-, -CR₂=CR₂- or -C≡C-,

wherein R₂ and the alkyl groups may be further substituted with 1 to 9

halo, -S(O)_mR_{2a}, 1 to 3 of -OR_{2a}, or -C(O)OR_{2a},

and wherein aryl is phenyl or naphthyl, and

- 4 -

heteroaryl is selected from indolyl, thiophenyl, furanyl, benzothiophenyl, benzofuranyl, pyridinyl, quinolinyl, triazolyl, imidazolyl, thiazolyl, and benzimidazolyl, wherein aryl and heteroaryl are unsubstituted or substituted with phenyl, phenoxy, halophenyl, 1 to 3 of -C₁-C₆ alkyl, 1 to 3 of halo, 1 to 2 of -OR₂, methylenedioxy, -S(O)_mR₂, 1 to 2 of -CF₃, -OCF₃, nitro, -N(R₂)(R₂), -N(R₂)C(O)(R₂), -C(O)OR₂, -C(O)N(R₂)(R₂), -SO₂N(R₂)(R₂), -N(R₂)SO₂-aryl, or -N(R₂)SO₂R₂;

10 R_{1a} is hydrogen or C₁-C₄ alkyl;

R₂ is selected from the group consisting of:

hydrogen, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, and -CH₂-phenyl,

wherein the alkyl or the cycloalkyl is unsubstituted or substituted with hydroxyl, C₁-C₃ alkoxy, thioalkyl, C(O)OR_{2a}, and wherein, if two C₁-C₆ alkyl groups are present on one atom, the groups may be optionally joined to form a C₃-C₈ cyclic ring optionally including oxygen, sulfur, or -NR_{2a}, the C₃-C₈ cyclic ring being selected from the group consisting of pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine;

R_{2a} is hydrogen or C₁-C₆ alkyl;

R₄ and R₅ are independently selected from the group consisting of:

hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl wherein the substituents may be 1 to 5 halo, 1 to 3 hydroxy, 1 to 3 C₁-C₁₀ alkanoyloxy, 1 to 3 C₁-C₆ alkoxy, phenyl, phenoxy, 2-furyl, C₁-C₆ alkoxycarbonyl, -S(O)_m(C₁-C₆ alkyl);

or wherein R₄ and R₅ may be taken together to form

-(CH₂)_rL_a(CH₂)_s-, wherein L_a is -C(R₂)₂-, -O-, -S(O)_m- or -N(R₂)-, wherein r and s are independently 1 to 3, and R₂ is as defined above;


- 5 -

R₆ and R₈ are independently selected from the group consisting of:
 hydrogen, -C₁-C₁₀ alkyl, -(CH₂)_t-aryl, -(CH₂)_qC(O)OR₂,
 -(CH₂)_qC(O)N(R₂)(R₂), -(CH₂)_q(C₃-C₆ cycloalkyl),
 -(CH₂)_q-K-(C₁-C₆ alkyl), -(CH₂)_q-K-(CH₂)_t-aryl,
 5 -(CH₂)_q-K-(CH₂)_t-(C₃-C₇ cycloalkyl),
 wherein K is -O-, -S(O)_m-, -CH=CH-, -C≡C-, -N(R₂)C(O)-,
 -C(O)NR₂-, -C(O)O-, or -OC(O)-,

wherein the alkyl, -R₂, -(CH₂)_q- and -(CH₂)_t- groups may be
 optionally substituted by -C₁-C₄ alkyl, hydroxyl, -C₁-C₄ alkoxy,
 10 carboxyl or carboxylate-C₁-C₄ esters, and
 wherein aryl is phenyl, unsubstituted or substituted with 1 to 3 halo,
 1 to 3 -OR₂, -C(O)OR₂, 1 to 3 -C₁-C₄ alkyl, -S(O)_mR₂, or
 1H-tetrazol-5-yl;

15 R₇ and R₉ are independently selected from the group consisting of:
 hydrogen, -C₁-C₁₀ alkyl, -(CH₂)_t-aryl; wherein aryl is phenyl,
 unsubstituted or substituted with 1 to 3 halo, 1 to 3 -OR₂, -C(O)OR₂,
 1 to 3 -C₁-C₄ alkyl, -S(O)_mR₂, or 1H-tetrazolyl;

20 A is:



25 wherein x and y are independently 0, 1, 2 or 3;

Z is -N(R₉)- or -O-, wherein R₉ is hydrogen or C₁-C₆ alkyl;

R₁₀ and R_{10a} are independently selected from the group consisting of:
 hydrogen, -C₁-C₆ alkyl, trifluoromethyl, phenyl, and
 substituted C₁-C₆ alkyl wherein the substituents are selected from the
 group consisting of: imidazolyl, phenyl, indolyl, p-hydroxyphenyl,
 30 -OR₂, -S(O)_mR₂, -C(O)OR₂, -C₃-C₇ cycloalkyl, -N(R₂)(R₂), and
 -C(O)N(R₂)(R₂);

or R₁₀ and R_{10a} may independently be joined to one or both of R₄ and
 R₅ groups to form alkylene bridges between the terminal nitrogen and the

- 6 -

alkyl portion of the R₁₀ or R_{10a} groups, wherein the bridge contains 1 to 5 carbons atoms;

- 5 B is selected from the group consisting of:
 phenyl, naphthyl, indolyl, thiophenyl, furanyl, benzothiopheneyl,
 benzofuranyl, pyridinyl, quinoliny, triazolyl, imidazolyl, thiazolyl,
 and benzimidazolyl, which is unsubstituted or substituted with one or
 more substituents selected from the group consisting of:
 10 hydrogen, -C₁-C₆ alkyl, -(CH₂)_t-(C₅-C₆ cycloalkyl),
 -(CH₂)_t-aryl, -O-R₂, -O-(CH₂)_t-aryl, -C(O)(CH₂)_t-aryl, cyano, nitro,
 halo, -(CH₂)_qOR₂, -(CH₂)_qCH(OR₂)R₂,
 -(CH₂)_qCH(OR₂)-(CH₂)_t-aryl,
 -(CH₂)_qC(O)OR₂, -(CH₂)_qC(O)O(CH₂)_t-aryl,
 15 -(CH₂)_qC(O)O(CH₂)_t-(C₅-C₆ cycloalkyl),
 -(CH₂)_qC(O)N(R₂)(R₂), -(CH₂)_qC(O)N(R₂)(CH₂)_t-aryl,
 -(CH₂)_qC(O)N(R₂)(CH₂)_t-(C₅-C₆ cycloalkyl),
 -(CH₂)_qN(R₂)C(O)(R₂), -(CH₂)_qN(R₂)C(O)(CH₂)_t-aryl,
 -(CH₂)_qN(R₂)C(O)N(R₂)(R₂),
 20 -(CH₂)_qN(R₂)C(O)N(R₂)(CH₂)_t-aryl,
 -(CH₂)_qN(R₂)C(O)OR₂,
 -(CH₂)_qN(R₂)C(O)O(CH₂)_t-aryl,
 -(CH₂)_qN(R₂)SO₂R₂, -(CH₂)_qN(R₂)SO₂(CH₂)_t-aryl,
 -(CH₂)_qSO₂R₂, -(CH₂)_qSO₂(CH₂)_t-aryl,
 -(CH₂)_qSO₂N(R₂)(R₂), -(CH₂)_qSO₂N(R₂)(CH₂)_t-aryl,
 25 -(CH₂)_qSO₂N(R₂)C(O)R₂, -(CH₂)_qSO₂N(R₂)C(O)-aryl,
 -(CH₂)_qC(O)NHSO₂R₂, -(CH₂)_q(1H-tetrazol-5-yl),
 -(CH₂)_q(imidazol-2-yl), -(CH₂)_q(1,2,4-triazol-1-yl),
 -(CH₂)_qCONH(1H-tetrazol-5-yl), -(CH₂)_qCONH(imidazol-2-yl), and
 30 -(CH₂)_qCONH(1,2,4-triazol-1-yl),
 wherein aryl is phenyl unsubstituted or substituted with 1 to 2 halo,
 amino, 1 to 2 -OR₂, or 1 to 2 -(C₁-C₄ alkyl);

m is 0, 1, or 2;

n is 1 or 2;

- 7 -

q is 0, 1, 2, 3 or 4;

t is 0, 1, 2 or 3;

5 and pharmaceutically acceptable salts and individual diastereomers thereof.

In the above structural formula and throughout the instant specification, the following terms have the indicated meanings:

10 The alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration which may optionally contain double or triple bonds. Exemplary of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, allyl, propinyl, butadienyl, hexenyl and the like.

15 The alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a straight or branched configuration which may optionally contain double or triple bonds. Exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy, allyloxy, propinyloxy, isobutenyloxy, hexenyloxy and the like.

The term "halo" or "halogen" is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.

25 The term "aryl" (unless otherwise specified) is intended to include phenyl and naphthyl. The term "heteroaryl" (unless otherwise specified) is intended to include aromatic residues of 5- and 6- membered rings with 1 to 3 heteroatoms or fused 5- or 6- membered bicyclic rings with 1 to 4 heteroatoms of nitrogen, sulfur or oxygen. Examples of such heteroaryl include indolyl, dihydroindolyl, thiophenyl, furanyl, benzothiophenyl, benzofuranyl, pyridinyl, pyrimidinyl, quinolinyl, triazolyl, imidazolyl, thiazolyl, tetrazolyl, and benzimidazolyl.

30 Certain of the above defined terms may occur more than once in the above formula and upon such occurrence each term shall be defined independently of the other, i.e. when any variable (e.g., alkyl,

- 8 -

aryl, R₂, etc.) occurs more than one time within any variable or in Formula I, its definition on each occurrence is independent of its definition at every other occurrence.

5 Preferred compounds of the instant invention include those of structural formula I wherein:

R₁ is selected from the group consisting of:

10 C₁-C₁₀ alkyl, aryl(C₁-C₄ alkyl)-, C₅-C₆ cycloalkyl-(C₁-C₄ alkyl)-, (C₁-C₄ alkyl)-K-C₁-C₂ alkyl-, aryl(C₀-C₂ alkyl)-K-(C₁-C₂ alkyl)-, C₃-C₆ cycloalkyl(C₀-C₂ alkyl)-K-(C₁-C₂ alkyl)-, wherein K is O or S(O)_m, and the aryl is phenyl, unsubstituted or substituted by 1 to 2
15 -C₁-C₄ alkyl, 1 to 2 halo, -OR₂, -C(O)OR₂, -CF₃ or -S(O)_mR₂;

R₂ is selected from the group consisting of:

20 hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, wherein the alkyl or the cycloalkyl is unsubstituted or substituted with hydroxyl, C₁-C₃ alkoxy, thioalkyl, C(O)OR_{2a}, and, if two C₁-C₆ alkyls are present on one atom, they may be optionally joined to form a C₅-C₆ cyclic ring optionally including the heteroatoms oxygen or NR_{2a}, the C₃-C₈ cyclic ring being selected from the group consisting of pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine,

25 R_{2a} is hydrogen or C₁-C₄ alkyl;

R₄ and R₅ are independently selected from the group consisting of:
30 hydrogen, C₁-C₄ alkyl, substituted C₁-C₄ alkyl wherein the substituents may be 1 to 2 hydroxy or S(O)_m(C₁-C₃ alkyl);


R₆ and R₈ are independently selected from the group consisting of:
hydrogen, -C₁-C₁₀ alkyl, -(CH₂)_t-aryl, -(CH₂)_qC(O)OR₂,
-(CH₂)_qC(O)N(R₂)(R₂), -(CH₂)_q(C₃-C₆ cycloalkyl),
-(CH₂)_n-K-(C₁-C₆ alkyl), -(CH₂)_n-K-(CH₂)_t-aryl,

- 9 -

- 5 $-(CH_2)_n-K-(CH_2)_t-(C_3-C_7 \text{ cycloalkyl})$, wherein K is $-O-$, $-S(O)_m-$, $-N(R_2)C(O)-$, $-C(O)NR_2-$, $-C(O)O-$, or $-OC(O)-$, wherein the alkyl, $-R_2$, $-(CH_2)_q-$ and $-(CH_2)_t-$ groups may be optionally substituted by $-C_1-C_4$ alkyl, hydroxyl, $-C_1-C_4$ alkoxy, carboxyl or carboxylate- C_1-C_4 esters, and wherein aryl is phenyl, unsubstituted or substituted with 1 to 3 halo, 1 to 3 $-OR_2$, $-C(O)OR_2$, 1 to 3 $-C_1-C_4$ alkyl, $-S(O)_mR_2$, or 1H-tetrazolyl;

- 10 R_7 and R_9 are independently selected from the group consisting of: hydrogen, $-C_1-C_{10}$ alkyl, $-(CH_2)_t$ -aryl, wherein the aryl group may be optionally substituted with 1 to 3 halo, 1 to 3 $-OR_2$, $-C(O)OR_2$, 1 to 3 $-C_1-C_4$ alkyl, $-S(O)_mR_2$ or 1H-tetrazol-5-yl;

- 15 A is:



20

wherein x is 0 or 1;

- R_{10} and R_{10a} are independently selected from the group consisting of: hydrogen, and C_1-C_3 alkyl; or R_{10} and R_{10a} can independently be joined to one or both of the R_4 and R_5 groups to form alkylene bridges between the terminal nitrogen and the alkyl portion of the R_{10} or R_{10a} groups to form 5 or 6 membered rings containing the terminal nitrogen;

- 25 B is selected from the group consisting of: phenyl, indolyl, pyridinyl, and pyrimidinyl, unsubstituted or substituted with one or more substituents selected from the group consisting of:

hydrogen, $-C_1-C_6$ alkyl, $-(CH_2)_t-(C_5-C_6 \text{ cycloalkyl})$, $-(CH_2)_t$ -aryl, $-O-R_2$, $-O-(CH_2)_t$ -aryl, $-C(O)(CH_2)_t$ -aryl, cyano, nitro, halo, $-(CH_2)_qOR_2$, $-(CH_2)_qCH(OR_2)R_2$, $-(CH_2)_qCH(OR_2)-(CH_2)_t$ -aryl,

30

- 10 -

- (CH₂)_qC(O)OR₂, -(CH₂)_qC(O)O(CH₂)_t-aryl,
 -(CH₂)_qC(O)O(CH₂)_t-(C₅-C₆ cycloalkyl),
 -(CH₂)_qC(O)N(R₂)(R₂), -(CH₂)_qC(O)N(R₂)(CH₂)_t-aryl,
 -(CH₂)_qC(O)N(R₂)(CH₂)_t-(C₅-C₆ cycloalkyl),
 5 -(CH₂)_qN(R₂)C(O)(R₂), -(CH₂)_qN(R₂)C(O)(CH₂)_t-aryl,
 -(CH₂)_qN(R₂)C(O)N(R₂)(R₂),
 -(CH₂)_qN(R₂)C(O)N(R₂)(CH₂)_t-aryl,
 -(CH₂)_qN(R₂)C(O)OR₂,
 -(CH₂)_qN(R₂)C(O)O(CH₂)_t-aryl,
 10 -(CH₂)_qN(R₂)SO₂R₂, -(CH₂)_qN(R₂)SO₂(CH₂)_t-aryl,
 -(CH₂)_qSO₂R₂, -(CH₂)_qSO₂(CH₂)_t-aryl,
 -(CH₂)_qSO₂N(R₂)(R₂), -(CH₂)_qSO₂N(R₂)(CH₂)_t-aryl,
 -(CH₂)_qSO₂N(R₂)C(O)R₂, -(CH₂)_qSO₂N(R₂)C(O)-aryl,
 -(CH₂)_qC(O)NHSO₂R₂, -(CH₂)_q(1H-tetrazol-5-yl),
 15 -(CH₂)_q(imidazol-2-yl), -(CH₂)_q(1,2,4-triazol-1-yl),
 -(CH₂)_qCONH(1H-tetrazol-5-yl), -(CH₂)_qCONH(imidazol-2-yl), and
 -(CH₂)_qCONH(1,2,4-triazol-1-yl),

wherein aryl is phenyl, unsubstituted or substituted with 1 to 2 halo,
 20 amino, 1 to 2 -OR₂, or 1 to 2 -(C₁-C₄ alkyl),

m is 0, 1 or 2;

n is 1 or 2;


q is 0, 1, 2 or 3;

25 t is 0, 1, 2 or 3;

and pharmaceutically acceptable salts and individual diastereomers
 thereof.


- 11 -

Most preferred compounds of the instant invention are realized in structural formula V:



15

wherein R₁ is selected from the group consisting of:



B is phenyl unsubstituted or substituted with one or more substituents selected from the group consisting of:

hydrogen,

-(CH₂)_t-aryl, C₁-C₃ alkyl, -(CH₂)_qOR₂,

- 12 -

- 5 $-(CH_2)_qC(O)OR_2$, $-(CH_2)_qC(O)O(CH_2)_t\text{-aryl}$,
 $-(CH_2)_qC(O)N(R_2)(R_2)$, $-(CH_2)_qC(O)N(R_2)(R_2)$,
 $(CH_2)_qC(O)N(R_2)(CH_2)_t\text{-aryl}$,
 $-(CH_2)_qN(R_2)C(O)(R_2)$, $-(CH_2)_qN(R_2)C(O)N(R_2)(R_2)$,
 $-(CH_2)_qN(R_2)C(O)OR_2$,
 $-(CH_2)_qN(R_2)SO_2R_2$, $-(CH_2)_qN(R_2)SO_2(CH_2)_t\text{-aryl}$,
 $-(CH_2)_qSO_2R_2$, $-(CH_2)_qSO_2(CH_2)_t\text{-aryl}$,
 $-(CH_2)_qSO_2N(R_2)(R_2)$, $-(CH_2)_qSO_2N(R_2)(CH_2)_t\text{-aryl}$,
 10 $-(CH_2)_qSO_2N(R_2)C(O)R_2$, $-(CH_2)_qSO_2N(R_2)C(O)\text{-aryl}$,
 $-(CH_2)_qC(O)NHSO_2R_2$, $-(CH_2)_q(1H\text{-tetrazol-5-yl})$,
 $-(CH_2)_q(\text{imidazol-2-yl})$, $-(CH_2)_q(1,2,4\text{-triazol-1-yl})$,
 $-(CH_2)_qCONH(1H\text{-tetrazol-5-yl})$, $-(CH_2)_qCONH(\text{imidazol-2-yl})$, and
 $-(CH_2)_qCONH(1,2,4\text{-triazol-1-yl})$,

15 wherein aryl is phenyl unsubstituted or substituted with 1 to 2 halo,
 amino, 1 to 2 $-OR_2$, or 1 to 2 $-(C_1-C_4\text{ alkyl})$;

20 R_2 is selected from the group consisting of:
 hydrogen, $-C_1-C_6$ alkyl, $-C_3-C_7$ cycloalkyl, and $-CH_2\text{-phenyl}$, optionally
 substituted with hydroxyl, $C_1-C_3\text{-alkoxy}$, thiomethyl, $-C(O)OR_{2a}$,
 wherein if two $-C_1-C_6$ alkyl groups are present on one atom, the groups
 may be optionally joined to form a C_3-C_4 cyclic ring optionally
 including oxygen, sulfur or $-NR_{2a}$;

25 R_{2a} is hydrogen or C_1-C_6 alkyl;

q is 0, 1, 2 or 3;


t is 0, 1, or 2;

30 and the pharmaceutically acceptable salts and individual diastereomers
 thereof.

- 13 -


Representative most preferred growth hormone releasing compounds of the present invention include the following:

5




10

15






20

25






30




- 14 -






- 15 -





- 16 -



- 17 -



- 18 -



and the pharmaceutically acceptable salts thereof.

Throughout the instant application, the following abbreviations are used with the following meanings:

BOC	t-butyloxycarbonyl
BOP	Benzotriazol-1-yloxy tris(dimethylamino)- phosphonium hexafluorophosphate
CBZ	Benzyloxycarbonyl
DIBAL-H	diisobutylaluminum hydride
DMF	N,N-dimethylformamide
EDC	1-(3-dimethylaminopropyl)-3-ethylcarbodi- imide hydrochloride
FAB-MS	Fast atom bombardment-mass spectroscopy


- 19 -

	GHRP	Growth hormone releasing peptide
	HOBT	Hydroxybenztriazole
	LAH	Lithium aluminum hydride
	HPLC	High pressure liquid chromatography
5	MHz	Megahertz
	MPLC	Medium pressure liquid chromatography
	NMM	N-Methylmorpholine
	NMR	Nuclear Magnetic Resonance
	TFA	Trifluoroacetic acid
10	THF	Tetrahydrofuran
	TLC	Thin layer chromatography
	TMS	Tetramethylsilane

15 The compounds of the instant invention all have at least one asymmetric center as noted by the asterisk in the structural Formula I above. Additional asymmetric centers may be present on the molecule depending upon the nature of the various substituents on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, 20 pure or partially purified optical isomers, racemic mixtures or diastereomeric mixtures thereof, be included within the ambit of the instant invention. In the case of the asymmetric center represented by the asterisk in Formula I, it has been found that the absolute stereochemistry of the more active and thus more preferred isomer is as shown in Formula Ia. With the R_{1a} substituent as hydrogen, the 25 special configuration of the asymmetric center corresponds to that in a D-amino acid. In most cases this is also designated an R-configuration although this will vary according to the values of R₁ and R_{1a} used in making R- or S- stereochemical assignments.

30

- 20 -



Formula Ia

The instant compounds are generally isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids. Examples of such acids are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic, methane sulfonic and the like. In addition, certain compounds containing an acidic function such as a carboxy may be isolated in the form of their inorganic salt in which the counterion may be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.

The preparation of compounds of Formula I of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses detailing the preparation of the compounds of Formula I in a sequential manner are presented in the following reaction schemes.


The phrase standard peptide coupling reaction conditions is used repeatedly here, and it means coupling a carboxylic acid with an amine using an acid activating agent such as EDC, DCC, and BOP in a inert solvent such as dichloromethane in the presence of a catalyst such as HOBt. The uses of protective groups for amine and carboxylic acid to facilitate the desired reaction and minimize the undesired reaction are well documented. Conditions required to remove protecting groups which may be present and can be found in Greene, T; Wuts, P. G. M. *Protective Groups in Organic Synthesis*, John Wiley & Sons, Inc., New York, NY 1991. CBZ and BOC were used extensively in the synthesis, and their removal conditions are known to those skilled in the art.

- 21 -


Removal of CBZ groups may be achieved by a number of methods known in the art; for example, catalytic hydrogenation with hydrogen in the presence of a noble metal or its oxide such as palladium on activated carbon in a protic solvent such as ethanol. In cases where catalytic
5 hydrogenation is contraindicated by the presence of other potentially reactive functionality, removal of CBZ groups may also be achieved by treatment with a solution of hydrogen bromide in acetic acid, or by treatment with a mixture of TFA and dimethylsulfide. Removal of BOC
10 protecting groups is carried out in a solvent such as methylene chloride or methanol or ethyl acetate, with a strong acid, such as trifluoroacetic acid or hydrochloric acid or hydrogen chloride gas.

The protected amino acid derivatives **1** are, in many cases, commercially available, where the protecting group L is, for example, BOC or CBZ groups. Other protected amino acid derivatives **1** may be
15 prepared by literature methods (Williams, R. M. *Synthesis of Optically Active α -Amino Acids*, Pergamon Press: Oxford, 1989). Many of the piperazines of formula **2** are either commercially available or known in the literature and others may be prepared following literature methods
20 described for known compounds, some of which are described here. The skills required in carrying out the reaction and purification of the resulting reaction products are known to those in the art. Purification procedures includes crystallization, normal phase or reverse phase
25 chromatography.

- 22 -


REACTION SCHEME 1

Intermediates of formula 3 may be synthesized as described in Reaction Scheme 1. Coupling of amine of formula 2, whose preparation is described later (if not commercially available), to protected amino acids of formula 1, wherein L is a suitable protecting group, may be conveniently carried out employing standard peptide coupling conditions.

REACTION SCHEME 2


Conversion of 3 to intermediate 4 may be carried out as illustrated in Reaction Scheme 2 by removal of the protecting group L (CBZ, BOC, etc.) by methodology well known in the art.

- 23 -

REACTION SCHEME 3

Intermediates of formula 5, wherein A is connected to the carboxyl by a carbon atom (i.e. A is $-(CH_2)_x-C(R_{10})(R_{10a})-(CH_2)_y-$) may be prepared as shown in Reaction Scheme 3 by coupling intermediates of formula 4 to amino acids of formula 5 under the standard peptide coupling reaction conditions. The amino acids 5, as amino acid 1, are either commercially available or may be synthesized. Also if R₄ or R₅ is a hydrogen then the protected amino acids 6 are employed in the coupling reaction, wherein L is a protecting group as defined above. The removal of L in 7 to afford I, where R₄ = H, may be carried out under conditions known in the art.

- 24 -

REACTION SCHEME 4

Compounds of formula I wherein R4 and/or R5 is a


15 hydrogen may be further elaborated to new compounds 7a with preferred side chains $R_4 = \text{CH}_2\text{-CH(OH)-CH}_2\text{X}$, wherein $\text{X} = \text{H}$ or OH) which are substituted on the amino group as depicted in Reaction Scheme 4.

Reductive alkylation of I with an aldehyde is carried out under conditions known in the art; for example, by catalytic hydrogenation with hydrogen

20 in the presence of platinum, palladium, or nickel catalysts or with chemical reducing agents such as sodium cyanoborohydride in a protic solvent such as methanol or ethanol in the presence of catalytic amount of acid. Alternatively, a similar transformation may be accomplished via an


25 epoxide opening reaction.

- 25 -

REACTION SCHEME 5

Compounds of formula I, wherein A is Z-(CH₂)_x-C(R₁₀)(R_{10a})-(CH₂)_y and Z is N-R₆ or O may be prepared as shown in Reaction Scheme 5 by reacting 4 with reagents 8, wherein X is a good leaving group such as Cl, Br, I, or imidazole. Alternatively, 4 may be reacted with an isocyanate of formula 9 in an inert solvent such as 1,2-dichloroethane to provide compounds of formula I where Z is NH.

The compounds of general formula I of the present invention may also be prepared in a convergent manner as described in reaction Reaction Schemes 6, 7 and 8.


REACTION SCHEME 6

- 26 -

The carboxylic acid protected amino acid derivatives 10 are, in many cases, commercially available where M = methyl, ethyl, or benzyl esters. Other ester protected amino acids may be prepared by classical methods familiar to those skilled in the art. Some of these methods include the reaction of the amino acid with an alcohol in the presence of an acid such as hydrochloric acid or p-toluenesulfonic acid and azeotropic removal of water. Other reactions include the reaction of a protected amino acid with a diazoalkane, or with an alcohol and an acid activating agent such as EDC, DCC in the presence of a catalyst such as DMAP and removal of the protecting group L.

Intermediates of formula 11 or 11a, may be prepared as shown in Reaction Scheme 6 by coupling of amino acid ester 10 to amino acids of formula 6 or 7. When a urea linkage is present in 11 or 11a, it may be introduced as illustrated in Reaction Scheme 5.

REACTION SCHEME 7




Conversion of the ester 11 or 11a to intermediate acids 12 or 12a may be achieved by a number of methods known in the art as described in Reaction Scheme 7. For example, methyl and ethyl esters may be hydrolyzed with lithium hydroxide in a protic solvent like aqueous methanol. In addition, removal of benzyl group may be accomplished by a number of reductive methods including hydrogenation in the presence of palladium catalyst in a protic solvent such as methanol. An allyl ester may be cleaved with tetrakis-triphenylphosphine palladium

- 27 -

catalyst in the presence of 2-ethylhexanoic acid in a variety of solvents including ethyl acetate and dichloromethane (see *J. Org. Chem.* 1982, 42, 587).

5

REACTION SCHEME 8


Acid 12 or 12a may then be elaborated to I or compound 7 as described in Reaction Scheme 8. Coupling of piperazines of formula 2 to acids of formula 12 or 12a, wherein L is a suitable protecting group, is conveniently carried out under the standard peptide coupling reaction conditions. Transformation of 7 to I is achieved by removal of the protecting group L. When R₄ and/or R₅ is H, substituted alkyl groups may be optionally added to the nitrogen atom as described in Reaction Scheme 4.

The substituted piperazines are either commercially available or may be prepared by literature procedures. Illustrated here are some, but by no means all, the methods for their preparation. Other methods will be readily apparent to one skilled in the art from the disclosure herein.

The carboxylic acid functionality at the 2-position of these compounds may be converted to ester, amide, acyl sulfonamide, and moieties according to the conventional methods well documented in the literature and known to those skilled in the art (*The Practice of Peptide*


- 28 -

Synthesis, by M. Bodanszky and A. Bodanszky, Springer-Verlag, 1984). L is an appropriate protecting group such as BOC, CBZ, etc. The carboxylic acid may also be converted into its next higher homologue, or to a derivative of the homologous acid, such as amide or ester by an Arndt-Eistert reaction. Alternatively, the ester may be directly homologated by the protocol using enolate anions described by C. J. Kowalski and R. E. Reddy in *J. Org. Chem.*, **57**, 7194-7208 (1992). The resulting acid and/or ester may be converted to the next higher homologue, and so on and so forth.

REACTION SCHEME 9


The synthesis of substituted aryl and heteroaryl piperazines has been detailed in a number of research articles. One of the standard approaches to the synthesis of aryl and heteroaryl piperazines involves a nucleophilic aromatic substitution reaction as shown in Scheme 9. The reaction of a protected piperazine of formula 13 (L = BOC, CBZ, etc.) with a halo-aromatic reactant of formula 14 (B-X; wherein X = Cl, F, Br, or I; usually F) in the presence of a base and/or Cu gives substituted piperazines 15 (L = BOC, CBZ, etc.). Removal of the protecting group L can be accomplished by methods familiar to those skilled in the art. These deblocked piperazines may be readily elaborated to the growth hormone secretagogues of formula I employing methodology detailed in Schemes 1-8.

- 29 -

REACTION SCHEME 10

Other methods that may be employed to prepare aryl and heteroaryl piperazines include the copper catalyzed N-arylation of amines by triarylbismuth diacetates (D.H.R. Barton, *et al.*, *Tetrahedron Lett.* 1986, 27, 3615-3618) as shown in Scheme 10.

15

REACTION SCHEME 11

Another method that has been employed to synthesize aryl piperazines involves the elaboration of the piperazine unit from anilines via a multistep sequence as shown in Scheme 11.

30

Substituted piperazines may be prepared in optically active form by the methods of Ashton, *et al.*, (PCT Patent Publication WO 92/20661; U.S. Patent No. 5,292,726). Substituted piperazines are first reduced to substituted piperazines by standard methods including hydrogenation with Pd/C in aqueous alkali. Separation of the

- 30 -

enantiomers is carried out by classical resolution with recrystallization of the salt derived from an optically acid like camphor sulfonic acid.

REACTION SCHEME 12

5


10

15

20


25

30



For the synthesis of compounds of formula I, the piperazine nucleus may be constructed by various methods. One such useful method, shown in Scheme 12, entails catalytic hydrogenation of a substituted pyrazine 17 to give the piperazine 18 (E. Felder, *et al.*, *Helv. Chim. Acta*, **43**, 888 (1960)). This is typically accomplished by use of palladium on carbon as the catalyst, in a solvent such as ethanol or water, at a temperature of 20-50°C.


- 31 -

REACTION SCHEME 13

Another method (Scheme 13) involves reaction of a protected diamine 19 with a dibromo compound 20 in the presence of base at elevated temperature to give the bis-protected piperazine 21, which yields 18 upon deprotection. This method has been particularly useful in cases where 20 is a 2,3-dibromo ester. In the variation used by Piper, *et al.*, (J.R. Piper, L.M. Rose, and T.P. Johnston, *J. Org. Chem.*, **37**, 4476 (1972)), the protecting group L is p-toluenesulfonyl, and the disodium salt of 19 is heated with 20 (R₆ or R₈ = CO₂Et) in DMF at up to about 100-110°C to form the piperazine 21. The p-toluenesulfonyl protecting groups can be removed (along with simultaneous ester hydrolysis) by heating 21 at reflux in 48% HBr (F.L. Bach, Jr., *et al.*, *J. Am. Chem. Soc.*, **77**, 6049 (1955)). In another variation (E. Jucker and E. Rissi, *Helv. Chim. Acta*, **45**, 2383 (1962)), the protecting group L is benzyl, and heating 19 with 20 (R₆ or R₈ = CO₂Et) in benzene yields 21. In this case deprotection is achieved (without ester hydrolysis) by palladium-catalyzed hydrogenation in acetic acid.

- 32 -


REACTION SCHEME 14




Another route to piperazine-2-carboxylic acids is illustrated in Scheme 14. The α -Cbz-protected α,β -diamino ester 22 is reacted with α -bromo ester 23. Following hydrogenolysis of the Cbz group, the oxopiperazinecarboxylate 24 is obtained. Selective reduction and hydrolysis affords the piperazinecarboxylic acid 25. This route (B. Aebischer, *et al.*, *Helv. Chim. Acta*, **72**, 1043 (1989)) has been used to prepare chiral piperazine-2-carboxylic acid from a chiral diamino ester 22. Optically active piperazine-2-carboxylic acids have also been obtained from the racemate via a camphorsulfonic acid salt (E. Felder, *Helv. Chim. Acta*, **43**, 888 (1960)) or menthyl ester (B. Aebischer, *et al.*, *Helv. Chim. Acta*, **72**, 1043 (1989)).

- 33 -


REACTION SCHEME 15




- 34 -

REACTION SCHEME 15 (CONT'D)

- 35 -

REACTION SCHEME 15 (CONT'D)

- 36 -

REACTION SCHEME 15 (CONT'D)

25 In compounds of formula I, the R₆, R₇, R₈ and R₉ substituents may be present at the time the piperazine ring system is formed, as shown in Schemes 9-14. However, additional transformations may be carried out on the R₆, R₇, R₈ and/or R₉ functional groups after elaboration of the diacylated (or carbamoylated, etc.) piperazine, as

30 shown in Scheme 15. For example, piperazinecarboxylic acid **26** may be readily converted to its methyl ester **27** by treatment with diazomethane, preferably in ether-methanol or THF at 0-25°C (B. Aebischer, *et al.*, *Helv. Chim. Acta*, **72**, 1043 (1989); C.F. Bigge, *et al.*, *Tetrahedron Lett.*, **30**, 5193 (1990)) or by other methods (C.F. Bigge, *et al.*, *op. cit.*). The acid **26** may also be obtained by saponification of **27** under standard

- 37 -

conditions. The methyl ester **27** may also be reduced to alcohol **32** by treatment with sodium borohydride/methanol according to the procedures of Sugihara and Nishikawa (EPO Patent Publication EP 0,368,670).

5 Treatment of carboxylic acid **26** with DCC or EDAC/HOBt followed by amine **28** affords the amide **29**. Methyl ester **27** may be transformed to aldehyde **30** by use of diisobutylaluminum hydride under controlled conditions at -78°C . Alternatively, alcohol **32** can be oxidized to **30** by various methods, such as the use of catalytic tetrapropylammonium perruthenate (TPAP) and 4-methylmorpholine N-oxide (NMO) in the
10 presence of molecular sieves (W.P. Griffith, *et al.*, *J. Chem. Soc. Chem. Commun.*, 1625 (1987)). Using standard reductive alkylation conditions, **30** is reacted with amine **28** in the presence of sodium cyanoborohydride to give the aminomethylpiperazine **31**. Alcohol **32** may be converted to methyl ether **33** by use of dimethyl sulfate, 50% aqueous sodium
15 hydroxide, and a phase transfer catalyst (PTC) such as tetrabutylammonium hydrogen sulfate (A. Merz, *Angew. Chem. Int. Ed. Engl.*, **12**, 846 (1973)).


The acylsulfonamide derivative **34** is obtained by treating the carboxylic acid **26** with carbonyldiimidazole and then with the
20 sulfonamide, $\text{R}^{\text{III}}\text{SO}_2\text{NH}_2$, and DBU as base in a solvent such as THF. Treatment of alcohol **32** with the carbamoyl chloride **35** in the presence of a base such as N,N-diisopropylethylamine yields the carbamate **36**. Similarly, reaction of **32** with acid chloride **37** in the presence of a base like pyridine gives the acyloxymethylpiperazine **38**. The bromomethyl
25 intermediate **39** is available by treatment of alcohol **32** with triphenylphosphine and carbon tetrabromide. Displacement of the bromo group by a thiol **40** occurs in the presence of N,N-diisopropylethylamine as base to give the thioether **41**. Oxidation of **41** to the sulfoxide **42** or the sulfone **43** may be carried out with *m*-chloroperbenzoic acid
30 (MCPBA) in a solvent such as methylene chloride or acetic acid. Whether **42** or **43** is the major or exclusive product is dependent on the stoichiometry, reaction time, and temperature.

In addition to the methyl ester **27**, the carboxylic acid **26** may be converted into other esters **44**, for example by treatment with


- 38 -

carbonyldiimidazole and an alcohol, ROH, in the presence of catalytic sodium ethoxide (H.A. Staab and A. Mannschreck, *Chem. Ber.*, 95, 1284 (1962)). An α -(acyloxy)alkyl ester **46** may be obtained by reaction of **25** with an α -chloralyl ester **45** in the presence of triethylamine, sodium iodide, and tetrabutylammonium hydrogen sulfate as phase transfer catalyst (E.W. Petrillo, *et al.*, U.S. Patent 4,873,356 (1989)).

REACTION SCHEME 16



- 39 -

REACTION SCHEME 16 (CONT'D)

Preparation of 2-(2-hydroxyethyl)piperazines and 2-(2-aminoethyl)piperazines can be carried out as illustrated in Scheme 16. Treatment of 2-methylpyrazine with paraformaldehyde at 165°C (as described by Kitchen and Hanson, *J. Am. Chem. Soc.*, 1951, 73, 1838) provides hydroxyethyl derivatives 47, which may be reduced to 2-(2-hydroxyethyl)piperazine by hydrogenation in the presence of a platinum catalyst. Selective protection with trityl chloride provides the

- 40 -


bisprotected compound 48, which may be deprotected to amino alcohol 49; which may be converted to bromide 50 with triphenylphosphine dibromide. Treatment with the appropriate amine or alcohol leads to the corresponding substituted amines 51 or ethers 52 respectively.

5

The aryl piperazines of Formula I can be further derivatized

The compounds of the present invention are prepared from a variety of substituted natural and unnatural amino acids such as those of formulas 60. The preparation of many of these acids is described in US Patent No. 5,206,237. The preparation of these intermediates in racemic form is accomplished by classical methods familiar to those skilled in the art (Williams, R. M. "Synthesis of Optically Active α -Amino Acids" Pergamon Press: Oxford, 1989; Vol. 7). Several methods exist to resolve (DL)-

15



20

60

amino acids. One of the common methods is to resolve amino or carboxyl protected intermediates by crystallization of salts derived from optically active acids or amines. Alternatively, the amino group of carboxyl protected intermediates may be coupled to optically active acids by using chemistry described earlier. Separation of the individual diastereomers either by chromatographic techniques or by crystallization followed by hydrolysis of the chiral amide furnishes resolved amino acids. Similarly, amino protected intermediates may be converted to a mixture of chiral diastereomeric esters and amides. Separation of the mixture using methods described above and hydrolysis of the individual diastereomers provides (D) and (L) amino acids. Finally, an enzymatic method to resolve N-acetyl derivatives of (DL)-amino acids has been reported by Whitesides and coworkers in *J. Am. Chem. Soc.* 1989, 111, 6354-6364.

25

30

- 41 -


When it is desirable to synthesize these intermediates in optically pure form, established methods include: (1) asymmetric electrophilic amination of chiral enolates (*J. Am. Chem. Soc.* **1986**, 108, 6394-6395, 6395-6397, and 6397-6399), (2) asymmetric nucleophilic
5 amination of optically active carbonyl derivatives, (*J. Am. Chem. Soc.* **1992**, 114, 1906; *Tetrahedron Lett.* **1987**, 28, 32), (3) diastereoselective alkylation of chiral glycine enolate synthons (*J. Am. Chem. Soc.* **1991**, 113, 9276; *J. Org. Chem.* **1989**, 54, 3916), (4) diastereoselective nucleophilic addition to a chiral electrophilic glycinate synthon (*J. Am.*
10 *Chem. Soc.* **1986**, 108, 1103), (5) asymmetric hydrogenation of prochiral dehydroamino acid derivatives ("Asymmetric Synthesis, Chiral Catalysis; Morrison, J. D., Ed; Academic Press: Orlando, FL, 1985; Vol 5), and (6) enzymatic syntheses (*Angew. Chem. Int. Ed. Engl.* **1978**, 17, 176).

For example, alkylation of the enolate of diphenyloxazinone
15 **61** (*J. Am. Chem. Soc.* **1991**, 113, 9276) with cinnamyl bromide in the presence of sodium bis(trimethylsilyl)amide proceeds smoothly to afford **62** which is converted into the desired (D)-2-amino-5-phenylpentanoic acid **63** by removing the N-t-butyloxycarbonyl group with trifluoroacetic
20 acid and hydrogenation over a PdCl₂ catalyst (Scheme 13).


25

30

- 42 -

SCHEME 17

Intermediates of formula 60 which are O-benzyl-(D)-serine derivatives 64 are conveniently prepared from suitably substituted benzyl halides and N-protected-(D)-serine 64. The protecting group L is conveniently a BOC or a CBZ group. Benzylation of 64 can be achieved by a number of methods well known in the literature including deprotonation with two equivalents of sodium hydride in an inert solvent such as DMF followed by treatment with one equivalent of a variety of benzyl halides (*Synthesis* 1989, 36) as shown in Scheme 18.


SCHEME 18

The O-alkyl-(D)-serine derivatives are also prepared using the alkylation protocol shown in Scheme 15. Other methods that could be utilized to prepare (D)-serine derivatives of formula 65 include the acid catalyzed benzylation of carboxyl protected intermediates derived

- 43 -

from **64** with reagents of formula $\text{ArCH}_2\text{OC}(=\text{NH})\text{CCl}_3$ (O. Yonemitsu *et al.*, *Chem. Pharm. Bull.* **1988**, 36, 4244). Alternatively, alkylation of the chiral glycine enolates (*J. Am. Chem. Soc.* **1991**, 113, 9276; *J. Org. Chem.* **1989**, 54, 3916) with $\text{ArCH}_2\text{OCH}_2\text{X}$ where X is a leaving group affords **35**. In addition D,L-O-aryl(alkyl)serines may be prepared and resolved by methods described above.

REACTION SCHEME 19




The synthesis of functionalized phenyl-piperazines of formula **66** can be carried out as shown in Scheme 19. Addition of the commercially available piperazine **67** to o-fluorobenzonitrile **68** proceeds well in the presence of potassium carbonate in DMF. Reduction of nitrile to amine **69** can be carried out by hydrogenation with Raney nickel in methanolic ammonia. The phenyl piperazine intermediate **69** can be derivatized in a variety of ways to obtain highly functionalized intermediates of formula **66**. Reaction of the amino unit of **69** with sulfonyl chlorides provides sulfonamides, isocyanides yields ureas, acid chlorides or acid anhydrides gives amides, sulfamoyl chlorides gives sulfamides, chloroformates gives carbamates

- 44 -


and so on and so forth. Removal of BOC protecting group with acid gives the functionalized intermediate 66 that can be elaborated to the secretagogues used chemistry detailed in Schemes 1-8.

5

REACTION SCHEME 20

The synthesis of functionalized phenyl-piperazines of formula 70 can be carried out as shown in Scheme 20. Addition of the commercially available piperazine 67 to o-fluoro-benzaldehyde 71 proceeds well in the presence of potassium carbonate in DMF. The phenyl piperazine intermediate 72 can be derivatized in a variety of ways to obtain highly functionalized intermediates of formula 70. A Horner-Emmons condensation of 72 with triethylphosphonoacetate and hydrogenation of the α,β -ester intermediate provides 73. Removal of the BOC group of 73 and elaboration to ester bearing GH secretagogues may be carried out by using chemistry detailed in Schemes 1-8.

- 45 -

REACTION SCHEME 21

As shown in Scheme 21 the ester unit of **73** can be transformed to the nitrile **74** in a straightforward manner. Reaction of **74** with trimethyltin azide in refluxing toluene provides the tetrazole **78** after removal the BOC protecting group. As shown previously, elaboration of **78** to the tetrazole bearing secretagogues can be carried out by using chemistry detailed in Schemes 1-8 after removal of the protecting group. Other functionalized phenyl piperazines of the formula **70** (wherein R_{12} is a carboxyl derivatized functionality) may be accessed from the intermediate **73** as shown in Scheme 21. The

- 46 -

ester unit of **73** can be hydrolyzed with aqueous alkali to give the acid intermediate **75**. Peptide type coupling of a variety of amines to **75** provides amides, alcohols gives esters, sulfonamides gives acylsulfonamides (for a procedure see R. T. Jacobs et al. *J. Med*
5 *Chem.* **1994**, *37*, 1282-1297). Again removal of the BOC protecting group from these functionalized phenyl piperazines and elaboration to the GH secretagogues is carried by using chemistry presented in Schemes 1-8.

10 The order of conducting the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products.

The growth hormone releasing compounds of Formula I are useful *in vitro* as unique tools for understanding how growth
15 hormone secretion is regulated at the pituitary level. This includes use in the evaluation of many factors thought or known to influence growth hormone secretion such as age, sex, nutritional factors, glucose, amino acids, fatty acids, as well as fasting and non-fasting states. In addition, the compounds of this invention may be used in
20 the evaluation of how other hormones modify growth hormone releasing activity. For example, it has already been established that somatostatin inhibits growth hormone release. Other hormones that are important and in need of study as to their effect on growth hormone release include the gonadal hormones, e.g., testosterone,
25 estradiol, and progesterone; the adrenal hormones, e.g., cortisol and other corticoids, epinephrine and norepinephrine; the pancreatic and gastrointestinal hormones, e.g., insulin, glucagon, gastrin, secretin; the vasoactive peptides, e.g., bombesin, the neurokinins; and the thyroid hormones, e.g., thyroxine and triiodothyronine. The compounds of
30 Formula I may also be employed to investigate the possible negative or positive feedback effects of some of the pituitary hormones, e.g., growth hormone and endorphin peptides, on the pituitary to modify growth hormone release. Of particular scientific importance is the use

- 47 -

of these compounds to elucidate the subcellular mechanisms mediating the release of growth hormone.

5 The compounds of Formula I may be administered to animals, including man, to release growth hormone *in vivo*. For example, the compounds may be administered to commercially important animals such as swine, cattle, sheep and the like to accelerate and increase their rate and extent of growth, to improve feed efficiency and to increase milk production in such animals. In addition, these compounds may be administered to humans *in vivo* as
10 a diagnostic tool to directly determine whether the pituitary is capable of releasing growth hormone. For example, the compounds of Formula I may be administered *in vivo* to children. Serum samples taken before and after such administration may be assayed for growth hormone. Comparison of the amounts of growth hormone in each of
15 these samples would be a means for directly determining the ability of the patient's pituitary to release growth hormone.

Accordingly, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of Formula I in association
20 with a pharmaceutical carrier or diluent. Optionally, the active ingredient of the pharmaceutical compositions may comprise an anabolic agent in addition to at least one of the compounds of Formula I or another composition which exhibits a different activity, e.g., an antibiotic growth permittant or an agent to treat osteoporosis or in
25 combination with a corticosteroid to minimize the catabolic side effects or with other pharmaceutically active materials wherein the combination enhances efficacy and minimizes side effects.

Growth promoting and anabolic agents include, but are not limited to, TRH, diethylstilbesterol, estrogens, β -agonists, theophylline, anabolic steroids, enkephalins, E series prostaglandins,
30 compounds disclosed in U.S. Patent No. 3,239,345, e.g., zeranol, and compounds disclosed in U.S. Patent No. 4,036,979, e.g., sulbenox or peptides disclosed in U.S. Patent No. 4,411,890.

- 48 -

A still further use of the growth hormone secretagogues of this invention is in combination with other growth hormone secretagogues such as the growth hormone releasing peptides GHRP-6, GHRP-1 as described in U.S. Patent No. 4,411,890 and PCT
5 Publications WO 89/07110, WO 89/07111 and B-HT920 as well as hexarelin and the newly discovered GHRP-2 as described in PCT Publication WO 93/04081 or growth hormone releasing hormone (GHRH, also designated GRF) and its analogs or growth hormone and its analogs or somatomedins including IGF-1 and IGF-2 or
10 α -adrenergic agonists such as clonidine or serotonin 5HT_{1D} agonists such as sumatriptan or agents which inhibit somatostatin or its release such as physostigmine and pyridostigmine. Preferred growth hormone secretagogues for combination therapy and/or compositions include GHRP-6, GHRP-2, GHRP-1, BHT920, GHRH, IGF-1 and
15 IGF-2.

As is well known to those skilled in the art, the recognized and potential uses of growth hormone are varied and multitudinous. Thus, the administration of the compounds of this invention for purposes of stimulating the release of endogenous
20 growth hormone may have the same effects or uses as growth hormone itself. These varied uses of growth hormone secretagogues may be summarized as follows: stimulating growth hormone release in elderly humans; treating growth hormone deficient adults; prevention of catabolic side effects of glucocorticoids, treatment of
25 osteoporosis; stimulation of the immune system, acceleration of wound healing, accelerating bone fracture repair, treatment of growth retardation, treating acute or chronic renal failure or insufficiency, treatment of physiological short stature, including growth hormone deficient children, treating short stature associated with chronic
30 illness, treatment of obesity and growth retardation associated with obesity, treating growth retardation associated with Prader-Willi syndrome and Turner's syndrome; accelerating the recovery and reducing hospitalization of burn patients or following major surgery such as gastrointestinal surgery; treatment of intrauterine growth

- 49 -

retardation, skeletal dysplasia, hypercortisonism and Cushings syndrome; replacement of growth hormone in stressed patients; treatment of osteochondrodysplasias, Noonan's syndrome, sleep disorders, Alzheimer's disease, delayed wound healing, and
5 psychosocial deprivation; treatment of pulmonary dysfunction and ventilator dependency; attenuation of protein catabolic response after a major operation; treating malabsorption syndromes, reducing cachexia and protein loss due to chronic illness such as cancer or AIDS; accelerating weight gain and protein accretion in patients on
10 TPN (total parenteral nutrition); treatment of hyperinsulinemia including nesidioblastosis; adjuvant treatment for ovulation induction and to prevent and treat gastric and duodenal ulcers; stimulation of thymic development and prevention of age-related decline of thymic function; adjunctive therapy for patients on chronic hemodialysis;
15 treatment of immunosuppressed patients and enhancement of antibody response following vaccination; improvement in muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis, renal hemeostasis in the frail elderly; stimulation of osteoblasts, bone remodelling, and cartilage growth; treatment of neurological diseases
20 such as peripheral and drug induced neuropathy, Guillian-Barre Syndrome, amyotrophic lateral sclerosis, multiple sclerosis, cerebrovascular accidents and demyelinating diseases; stimulation of the immune system in companion animals and treatment of disorders of aging in companion animals; growth promotant in livestock; and
25 stimulation of wool growth in sheep.

It will be known to those skilled in the art that there are numerous compounds now being used in an effort to treat the diseases or therapeutic indications enumerated above. Combinations of these
30 therapeutic agents, some of which have also been mentioned above, with the growth hormone secretagogues of this invention will bring additional, complementary, and often synergistic properties to enhance the growth promotant, anabolic and desirable properties of these various therapeutic agents. In these combinations, the therapeutic agents and the growth hormone secretagogues of this invention may be independently present in

- 50 -

dose ranges from one one-hundredth to one times the dose levels which are effective when these compounds and secretagogues are used singly.

5 Combined therapy to inhibit bone resorption, prevent osteoporosis and enhance the healing of bone fractures may be illustrated by combinations of bisphosphonates and the growth hormone secretagogues of this invention. The use of bisphosphonates for these utilities has been reviewed, for example, by Hamdy, N.A.T., Role of Bisphosphonates in Metabolic Bone Diseases. *Trends in Endocrinol. Metab.*, 1993, 4, 19-25. Bisphosphonates with these utilities include
10 alendronate, tiludronate, dimethyl-APD, risedronate, etidronate, YM-175, clodronate, pamidronate, and BM-210995, a preferred bisphosphonate being alendronate. According to their potency, oral daily dosage levels of the bisphosphonate of between 0.1 mg and 5 g and daily dosage levels of the growth hormone secretagogues of this invention of between 0.01
15 mg/kg to 20 mg/kg of body weight are administered to patients to obtain effective treatment of osteoporosis.

The compounds of this invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual, or
20 topical routes of administration and may be formulated in dosage forms appropriate for each route of administration.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically
25 acceptable carrier such as sucrose, lactose, or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills may additionally be prepared with
30 enteric coatings.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions may also

- 51 -

include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They may also be manufactured in the form of sterile solid compositions which may be dissolved in sterile water, or some other sterile injectable medium immediately before use.



Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax.

Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.

The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 0.0001 to 100 mg/kg. of body weight daily are administered to patients and animals, e.g., mammals, to obtain effective release of growth hormone.

The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the spirit or scope of the present invention.

- 52 -

INTERMEDIATE 1Step A:

To 5.0 g (16.5 mmole) of the commercially available N-t-
15 BOC-D-tryptophan in 100 mL of chloroform was added 1.80 mL (16.5 mmole) of benzyl alcohol, 0.20 g (1.65 mmole) of 4-N,N-dimethylamino pyridine (DMAP), and 3.20 g of EDC and stirred for 16h. The reaction mixture was poured into 100 mL of water and the organic layer was separated. The aqueous was further extracted with 2X100 mL of
20 chloroform. The combined organic solution was washed with 50 mL of 10% aqueous citric acid, 100 mL of 10% aqueous sodium bicarbonate solution, dried over anhydrous magnesium sulfate, filtered and concentrated to give a thick oil.

To a solution of this oil in 10 mL of dichloromethane was
25 added 20 mL of trifluoroacetic acid and stirred for 1h. The reaction mixture was concentrated, basified carefully with saturated aqueous sodium bicarbonate solution, and extracted with chloroform (2X100 mL). The combined organic solution were washed with brine (100 mL), dried over potassium carbonate, filtered, and concentrated to give 5.46 g of the
30 amine as a brown oil which was used without purification.


To 5.46 g of the above product in 100 mL of chloroform was added 3.40 g (22.2 mmole) of HOBt, 4.60 g (22.2 mmole) of N-BOC-a-methyl alanine, and 5.32 g (28.0 mmole) of EDC and stirred for 16h. The reaction mixture was poured into 100 mL of water and the organic layer was separated. The aqueous was further extracted with

- 53 -

2X100 mL of chloroform. The combined organic solution were washed with 50 mL of 10% aqueous citric acid, 100 mL of 10% aqueous sodium bicarbonate solution, dried over anhydrous magnesium sulfate, filtered and concentrated to give 6.94 g of the product as a thick oil. Flash chromatography (200 g SiO₂; hexane-ethyl acetate as eluent) gave 4.75 g of the desired material as a colorless foam.

¹H NMR (CDCl₃, 200MHz) δ 8.48 (bs, 1H), 7.54 (bd, 1H), 7.38-7.23 (m, 3H), 7.19 (bd, 2H), 7.15-7.00 (m, 1H), 6.90 (d, 1H), 6.86 (d, 1H), 5.06 (bs, 2H), 4.95 (ddd, 1H), 3.30 (2dd, 2H), 1.40 (s, 15H)


Step B:



To a solution of 4.75 g of the material from Step A in 100 mL of ethanol was added 1.0 g of 10% Pd/C and stirred at RT under a H₂ balloon for 18h. The catalyst was filtered off through a pad of celite and washed with ethyl acetate. The filtrate was concentrated to give 2.96 g of the acid as a colorless foam.

¹H NMR (CDCl₃, 200MHz) δ 8.60 (bs, 1H), 7.55 (d, 1H), 7.26-6.90 (m, 3H), 6.88 (bd, 1H), 4.80 (m, 1H), 3.32 (2dd, 2H), 1.37 (s, 3H), 1.35 (s, 12H).

INTERMEDIATE 2




This intermediate was synthesized as described in Step A and B of Intermediate 1, but (2R)-N-t-BOC-5-phenylpentanoic acid (H.

- 54 -

K. Chenault et al. *J. Am. Chem. Soc.* 1989, 111, 6354-6364)) was used in place of N-t-BOC-(D)-tryptophan.

¹H NMR (CDCl₃, 400MHz) δ 7.24-7.20 (m, 2H), 7.15-7.04 (m, 3H), 4.60-4.55 (m, 1H), 2.62-2.55 (m, 2H), 2.00-1.86 (m, 1H), 1.78-1.60 (m, 3H), 1.50 (s, 6H), 1.30 (s, 9H).

EXAMPLE 1



Step A:




A mixture of 5.0g of o-fluorobenzonitrile, 9.20g of N-t-BOC-piperazine, and 6.8g of powdered potassium carbonate was heated at 150°C in dry DMF for 4h and cooled to RT and stirred for 2 days. The reaction mixture was poured into 100mL of water and extracted with 3X50mL of ethyl acetate. The combined organics were washed with saturated aqueous ammonium chloride solution, 2x50mL of brine, dried over anhydrous MgSO₄ and concentrated. This material was reduced to the benzylamine derivative with Raney Nickel in ethanolic ammonia at 1000psi at 80°C for 24h. The catalyst was filtered off through a pad of celite and the filtrate was concentrated to give the title compound.

- 55 -

^1H NMR (400MHz; CDCl_3) δ 8.70 (bs, 2H), 7.42 (d, 1H), 7.34 (t, 1H), 7.20-7.07 (m, 2H), 4.19 (bs, 1H), 3.70-3.40 (m, 4H), 3.90-3.86 (m, 4H), 1.46 (s, 9H)

5 Step B:




To 0.12 g of the above material in 2mL of CH_2Cl_2 at 0°C was added 0.10mL of triethylamine and 0.031mL of methanesulfonyl chloride and stirred for 1h. The reaction mixture was diluted with 20mL of CH_2Cl_2 and washed with 20mL of saturated NaHCO_3 , 20mL of brine, dried over Na_2SO_4 and concentrated to give an oil which was used in the next step.

20 Approximately 0.10 g of the above intermediate was treated with $\text{CH}_2\text{Cl}_2/\text{TFA}$ for 1h at RT to remove the BOC protecting group. The reaction mixture was evaporated to dryness and basified with saturated NaHCO_3 and extracted with CH_2Cl_2 . The combined organics were washed with brine, dried over K_2CO_3 , filtered, and concentrated to give the piperazine intermediate that was used without purification.

25

30

- 56 -

Step C:

15 Approximately 40mg of the piperazine intermediate from Step B was coupled with 69mg of Intermediate 1 in dry CH_2Cl_2 in the presence of 10mg of HOBT and 42mg of EDC. The reaction mixture was diluted with CH_2Cl_2 and washed with saturated NaHCO_3 , brine, dried over Na_2SO_4 , filtered and concentrated. Purification of the crude product on silica gel with hexane-acetone (1:1) as the eluent gave the desired product.


20 The above intermediate was stirred in a mixture of TFA and CH_2Cl_2 for 20min. The reaction mixture was concentrated to dryness, basified with saturated NaHCO_3 , and extracted with CH_2Cl_2 . The crude product was purified by preparative Tlc on an 1mm plate with CH_2Cl_2 -MeOH (4:1) as the eluent. This gave a free base that was treated with saturated HCl in EtOAc for 15min. The reaction was diluted with ether and the precipitate was filtered to give the desired product.

25 ^1H NMR (400MHz, CDCl_3) δ 7.62 (d, 1H), 7.41-7.33 (m, 2H), 7.24 (m, 1H), 7.20-7.00 (m, 4H), 6.75 (d, 1H), 5.18 (ddd, 1H), 4.22 (ABq, 2H), 3.90 (bd, 1H), 3.46 (bd, 1H), 3.40-3.25 (m, 2H), 3.22-3.10 (m, 2H), 2.83 (s, 3H), 2.65 (bd, 1H), 2.43 (bd, 1H), 2.07 (bt, 1H), 1.62 (s, 3H), 1.60 (s, 3H), 1.50-1.40 (m, 1H)

30

- 57 -

EXAMPLE 2



To 0.30g the benzylamine intermediate prepared in Example 1 Step A in 2mL of dry CH_2Cl_2 was added 0.29mL of triethylamine and 0.10mL of methylisocyanate and stirred at RT for 40min. The reaction mixture was concentrated to give a solid.


¹H NMR (400MHz, CDCl₃) δ 7.30 (d, 1H), 7.22 (t, 1H), 7.10-6.90 (m, 2H), 5.32 (bs, 1H), 5.00 (bs, 1H), 4.66 (bs, 1H), 4.35 (bs, 2H), 3.53 (bs, 4H), 2.80 (bs, 3H), 2.80 (m, 4H), 1.47 (s, 9H)

20 The above solid was treated with 1mL of CH₂Cl₂ and 2mL of TFA to remove the BOC protecting group, worked-up and elaborated to the title compound as described in Example 1 Steps B & C.

¹H NMR (400MHz, CD₃OD) δ 8.60 (bs, 1H), 7.70-7.41 (m, 5H), 7.32 (bs, 1H), 7.19 (bt, 1H), 7.10 (bt, 1H), 5.20-5.10 (bs, 1H), 4.26 (bs, 2H), 3.70-3.55 (m, 4H), 3.40-3.31 (m, 6H), 2.67 (s, 3H), 1.66 (s, 6H)


30

- 58 -

EXAMPLE 3

The title compound was prepared by methodology described in Example 1 Steps A-C, but CBZ-Cl was used in place of methanesulfonyl chloride.

15 ^1H NMR (400MHz, CD_3OD) δ 7.66 (d, 1H), 7.50-7.00 (m, 12H), 6.83 (d, 1H), 5.30-5.20 (m, 1H), 5.07 (s, 2H), 3.86 (m, 1H), 3.40 (bd, 1H), 3.30-3.10 (3H), 2.60 (bd, 1H), 2.37 (bd, 1H), 2.06 (bs, 1H), 1.60 (s, 3H), 1.56 (s, 3H), 1.50-1.35 (m, 1H).

EXAMPLE 4

To a stirred solution of 0.15g of D-N-BOC-3-phenylpropyl glycine in 2mL of CH_2Cl_2 was added the piperazine methanesulfonamide derivative prepared in Example 1 Step B, 0.082g of HOBT, 0.147g of EDC and stirred at RT overnight. The reaction mixture was poured into

- 59 -

30mL of saturated NaHCO_3 solution, and extracted with 2X30mL of CH_2Cl_2 . The combined organics were washed with 20% aqueous citric acid, 30mL of brine, dried over MgSO_4 , and concentrated.

5 Approximately 0.10g of the above coupled product was treated with $\text{TFA}/\text{CH}_2\text{Cl}_2$ to remove the BOC protecting, the reaction mixture was evaporated to dryness, basified with Na_2CO_3 , and extracted with CH_2Cl_2 . The combined organics were washed with brine, dried over K_2CO_3 , filtered and concentrated.

10 Approximately 0.070g of the amine obtained above was coupled with N-BOC- α -methylalanine using the EDC/HOBT procedure described above. Purification of the residue by flash chromatography and removal of the BOC protecting with $\text{TFA}/\text{CH}_2\text{Cl}_2$ gave the title compound as the trifluoroacetate salt. FAB MS calcd for $\text{C}_{27}\text{H}_{39}\text{N}_5\text{O}_4\text{S}$ 529; found 530.8 (m+1)

15 Alternatively, the HCl salt may be obtained by treatment with dry HCl in EtOAc at ambient temperature for usually 30-60min.


EXAMPLES 5-8

20 Employing the methodology described in Example 4 the following compounds were prepared either as the free base or TFA or HCl salts.


25

30


- 60 -




Example No.	R	molecular formula	FAB MS m/e calc.	m/e found (m+1)
5	iPr	C ₂₉ H ₄₃ N ₅ O ₄ S	557.30	558.60
6	CO ₂ CH ₂ Ph	C ₃₉ H ₅₁ N ₅ O ₆	685	686.7
7	SO ₂ CH ₂ CO ₂ Me	C ₂₉ H ₄₁ N ₅ O ₆ S	587.28	588.5
8	SO ₂ CH ₂ COOH	C ₂₈ H ₃₉ N ₅ O ₆ S	573.26	574.5

EXAMPLE 9

- 61 -

Step A:


10 A mixture of 9.8g of N-tBOC-piperazine, 5.0g of 1-fluoro-2-nitrobenzene, and 7.3g of powdered potassium carbonate were heated in 10mL of dry DMF for 3h. The solids were filtered off through a pad of celite and washed with ether. The filtrate was washed with saturated aqueous NH₄Cl solution, back extracted with 100mL of ether. The ether
15 extracts were washed with brine, dried over MgSO₄ and concentrated to give the title compound.

Step B:

The phenyl piperazine intermediate prepared in Step A was elaborated by using chemistry presented for the preparation of the
30 intermediate obtained in Example 4 Step B.


¹H NMR (400MHz, CDCl₃) δ 7.79 (d, 1H), 7.50 (t, 1H), 7.28-7.00 (m, 7H), 5.00-4.80 (m, 2H), 3.80-3.52 (m, 3H), 3.50-3.37 (m, 1H), 3.05-2.85 (m, 4H), 3.00-3.86 (m, 2H), 2.80-2.73 (m, 1H), 2.70-2.50 (m, 2H), 1.80-1.60 (m, 5H), 1.48 (s, 3H), 1.46 (s, 3H), 1.40 (s, 9H)

- 62 -


Step C:

A solution of 12mg of the intermediate from Step B was treated with 0.50mL of TFA for 20min at RT. The volatiles were removed by rotary evaporation and the residue was triturated with ether to give the title compound as a solid.

15 ^1H NMR (400MHz, CD_3OD) δ 7.82 (d, 1H), 7.63 (t, 1H), 7.40-7.10 (m, 7H), 5.00-4.80 (m, 1H), 3.80-3.55 (m, 4H), 3.12-3.00 (m, 3H), 2.96-2.85 (m, 1H), 2.80-2.60 (m, 2H), 2.90-2.70 (m, 4H), 1.61 (s, 6H)


EXAMPLE 10

- 63 -

Step A:

A solution of 2.2g of the nitro intermediate prepared in Example 9 Step B was reduced to an aniline intermediate by hydrogenation with Raney nickel in 25mL of ethanol at 40psi for 3h. The catalyst was filtered through a pad of celite and washed with ethanol. Concentration of the filtrate gave the desired material.

^1H NMR (400MHz, CDCl_3) δ 7.27-7.05 (m, 5H), 6.92 (t, 1H), 6.83 (d, 1H), 6.72-6.69 (m, 2H), 4.96 (s, 1H), 4.95-3.86 (m, 1H), 4.20-3.50 (m, 4H), 2.95-2.54 (m, 6H), 1.80-1.52 (m, 2H), 1.60-1.40 (m, 2H), 1.50 (s, 3H), 1.44 (s, 3H), 1.42 (s, 9H)

Step B:

To 0.20g of the above intermediate in 10mL of CH_2Cl_2 at 0°C was added 0.080mL of N-methylmorpholine, and 0.043mL of methanesulfonylchloride and stirred for 1h. Routine work-up and flash chromatography of the residue over silica gel with hexane-ether (5:1) as

- 64 -


the eluent gave the desired material. Deprotection with TFA/CH₂Cl₂ gave the title compound.

m/e calcd. for C₂₆H₃₇N₅O₄S 515; found 516.7 (m+1)

Alternatively, the final deprotection may be conducted in HCl/EtOAc to provide the hydrochloride salts of the final products.


EXAMPLES 11-15

The following examples were prepared from the compound of Example 10 Step B.




Example No.	R	molecular formula	FAB MS m/e calc.	m/e found (m+1)
11	SO ₂ Ph	C ₃₂ H ₄₁ N ₅ O ₆ S	591	592.5
12	COCH ₂ CH ₂ CO ₂ H	C ₂₇ H ₃₉ N ₅ O ₅	537	538
13	SO ₂ CH ₂ CO ₂ Me	C ₂₈ H ₃₉ N ₅ O ₆ S	573	574.8
14	SO ₂ CH ₂ COOH	C ₂₇ H ₃₇ N ₅ O ₆ S	559	560.9
15	CO(CH ₃) ₃	C ₃₀ H ₄₃ N ₅ O ₃	521	522.9

- 65 -

EXAMPLE 16Step A:

Preparation of this compound was conducted using chemistry described for the preparation of the intermediate synthesized in Example 9 Step A, but o-fluorobenzaldehyde was used in place of o-fluorobenzonitrile.

Step B:

To a solution of 5.0g of the aldehyde prepared in Step A in 20mL of dry THF at 0°C 30 mL of a 2M solution of lithium borohydride

- 66 -


in THF and stirred at RT for 2h. The reaction was quenched with acetone and slowly poured into aqueous NH_4Cl solution and extracted with EtOAc. The combined organics were washed with brine, dried over MgSO_4 and concentrated.

5 To a solution of 1.4g of the alcohol in 10mL of CH_2Cl_2 at 0°C was added 1.3mL of triethylamine and 0.40mL of methanesulfonyl chloride and stirred till the reaction was complete as seen by tlc. Routine work-up gave the crude mesylate that was used without purification.

10 To a solution of 1.4g of the intermediate in 5mL of dry DMF was added 0.9g of sodium thiomethoxide and heated at 60°C overnight. The reaction mixture was cooled to RT, diluted with brine and extracted with ether. The combined organics were washed with brine, dried over MgSO_4 and concentrated. Flash chromatography of the residue with hexane-EtOAc (6:1) as the eluent gave the desired sulfide.

15 Approximately 0.20g of the above sulfide was treated with 2 portions of 0.20g of OXONE in 3mL of methanol-water (2:1) for 2h. The reaction mixture poured into brine and extracted with EtOAc (3X20mL). The combined organics were washed with brine (2X30mL), dried over MgSO_4 , filtered and concentrated. The residue was purified by
20 silica gel chromatography with hexane-EtOAc (1:1) as the eluent. The BOC protecting group was removed at this time with the TFA/ CH_2Cl_2 procedure and the free base was obtained after NaHCO_3 work-up.

25 Step C:




- 67 -


This material was prepared by methodology used to synthesize the intermediate made in Example 1 Step C, but Intermediate 2 was used in place of Intermediate 1. The BOC intermediate thereby obtained was treated with TFA/CH₂Cl₂ for 30min at RT and then diluted with ether to give a precipitate that was dried.

¹H NMR (400MHz, CD₃OD) δ 7.55 (d, 1H), 7.40 (t, 1H), 7.30-7.10 (m, 7H), 4.60 (s, 2H), 3.80-3.52 (m, 4H), 2.91 (s, 1H), 2.90-2.60 (m, 6H), 1.85-1.70 (m, 4H), 1.61 (s, 6H)

EXAMPLE 17



Step A:




To a solution of 2.23mmol of the mesylate intermediate prepared as described in Example 17 Step B in 10mL of dry DMF was added 0.243g of the sodium salt of 1,2,4-triazole and the resultant solution was stirred overnight. The reaction mixture was diluted with 15mL of EtOAc and washed with saturated NH₄Cl (10mL), brine (10mL), dried over MgSO₄ and concentrated to the triazole as a yellow solid.

- 68 -

¹H NMR (400MHz, CDCl₃) δ 8.05 (s, 1H), 7.86 (s, 1H), 7.36-7.05 (m, 4H), 5.40 (s, 2H), 3.48 (bs, 4H), 2.73 (bs, 4H), 1.43 (s, 9H) (this NMR also showed traces of DMF and 1,2,4-triazole).

5 Step B:




15 The above intermediate was deprotected, coupled with Intermediate 2, and finally deprotected by employing methodology described for the preparation of the intermediates in Example 1.

20 EXAMPLES 18-22

25 The following compounds were prepared employing methodology used to synthesize the title compound of Example 4 with the following modifications: a) N-BOC-D-tryptophan was used in place of D-3-phenylpropylglycine, b) either methanol/concentrated HCl or TFA/CH₂Cl₂ were used to remove the BOC protecting group. The characteristic NMR resonances reported are either for the salt form (in CD₃OD) or the free base obtained after basic work-up (in CDCl₃).



30

- 69 -




5	Example No.	R	Characteristic NMR Resonances (ppm)
10	18		8.35 (bd, 1H), 7.72 (bd, 1H), 5.28 (q, 1H), 2.1 (s, 3H), 2.2 (s, 3H)
15	19		7.6 (d, 1H), 7.35 (t, 2H), 6.80 (d, 1H), 5.22-5.15 (m, 1H), 2.93 (bd, 1H), 2.10 (t, 1H), 1.62 (s, 3H), 1.58 (s, 3H)
20	20		7.61 (d, 1H), 7.40 (d, 1H), 7.15 (t, 1H), 7.08 (t, 1H), 5.15-5.05 (m, 1H), 2.90-2.70 (m, 4H), 1.62 (s, 3H), 1.55 (s, 3H)
25	21		8.60 (d, 1H), 7.90 (d, 2H), 7.50 (t, 1H), 7.13 (t, 1H), 7.05 (t, 1H), 5.18 (t, 1H), 4.00 (bd, 1H), 3.10 (bd, 1H), 2.17 (t, 1H), 1.33 (s, 6H)
30	22		8.50 (d, 1H), 8.00 (d, 1H), 7.65 (d, 1H), 7.40 (d, 1H), 5.35-5.20 (m, 1H), 2.90-2.70 (m, 1H), 2.40-2.20 (m, 1H), 1.70 (s, 3H), 1.61 (s, 3H)

- 70 -

EXAMPLE 23Step A:

A mixture of 500 mg of piperazine-4-CBZ-2-carboxylic acid (*J. BioMed. Chem. Lett.* 1993, 3, 2023), and 164 ml of thionyl chloride was refluxed in methanol for 12 hours and cooled to RT. The resulting mixture was concentrated. The residue in chloroform was washed with 1 N NaOH, brine, dried over anhydrous potassium carbonate and concentrated to give the title compound (419 mg).


Step B:

To a solution of the above material (337 mg) in chloroform was added di-*t*-butyl dicarbonate at RT. After stirring for 3 hours, the mixture was concentrated. The residue in methanol was hydrogenated

- 71 -

over a catalytic amount of Pd(OH)₂ at one atmosphere. The mixture was stirred for 12 hours and then filtered through Celite. The filtrate was concentrated to give the title compound (295 mg).

5 Step C:




10 A mixture of the above material (250 mg), o-fluoronitrobenzene (129 ml) and potassium carbonate (168 mg) was heated at 100°C in DMF for 12 hours. The mixture was poured into water and extracted with ether (3X). The organic layers were washed with water (5X), brine, dried over sodium sulfate and concentrated. The residue was purified by
15 PLC (hexanes/ethyl acetate=5/1) to give the title compound (250 mg).
20 ¹H NMR (CDCl₃, 400 MHz): δ 7.66 (d, 8 Hz, 1 H), 7.47 (t, 8 Hz, 1 H), 7.17 (d, 8 Hz, 1 H), 7.12 (t, 8 Hz, 1 H), 4.81 (s, 1/2 H), 4.62 (s, 1/2 H), 3.95-3.35 (m, 4 H), 3.77 (s, 3/2 H), 3.75 (s, 3/2 H), 3.17-3.07 (m, 2 H), 2.86 (m, 1 H), 1.47 (s, 9/2 H), 1.43 (s, 9/2 H).


25

30

- 72 -

Step D:

To the intermediate prepared in Step C (250 mg) was added 2 ml of TFA. After 10 minutes, the mixture was concentrated. The residue was dissolved in chloroform and washed with 1 N NaOH, brine and dried over potassium carbonate. The organic layer was concentrated. The residue in 5 ml of chloroform was coupled with Intermediate 1 (255 mg) in the presence of BOP reagent (450 mg). After stirring for 12 hours, the mixture was poured into water and extracted with methylene chloride, dried over sodium sulfate and concentrated. The residue was purified by chromatatron (hexanes/ethyl acetate=1/1) to give the desired product (140mg).


Step E:

Through a solution of the above intermediate (5 mg) in ethyl acetate was bubbled HCl(g) at 0°C for 15 seconds. After standing for 30


- 73 -

minutes, the mixture was concentrated to give the title compound (4.3 mg). FAB-MS: 537.5 (M+1).

EXAMPLE 24




Step A:



The intermediate obtained from Example 23, Step D (130 mg) was reduced to the aniline derivative with Raney Nickel in methanol at 50 psi for 12 hours. The catalyst was filtered off through Celite and the filtrate was concentrated to give the title compound (65 mg).

Step B:

- 74 -




To the intermediate obtained from Step A (13 mg), in chloroform was added methyl isocyanate (4ml) and refluxed for 3 hours. The mixture was concentrated and purified by chromatatron (methylene chloride/ methanol=20/1) to give desire product. The above intermediate in ethyl acetate was bubbled though HCl(g) at 0°C for 15 seconds. After standing for 30 minutes, the mixture was concentrated to give the title compound (8.9 mg). FAB-MS: 564.3 (M+1).

While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. For example, effective dosages other than the particular dosages as set forth herein above may be applicable as a consequence of variations in the responsiveness of the mammal being treated for any of the indications with the compounds of the invention indicated above. Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compounds selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be defined by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

- 75 -

WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein:

R₁ is selected from the group consisting of:

C₁-C₁₀ alkyl-, aryl-, aryl(C₁-C₆ alkyl)-,

heteroaryl-, heteroaryl(C₁-C₆ alkyl)-,

(C₃-C₇ cycloalkyl)-(C₁-C₆ alkyl)-,

(C₁-C₅ alkyl)-K-(C₁-C₅ alkyl)-,

aryl-(C₀-C₅ alkyl)-K-(C₁-C₅ alkyl)-,

heteroaryl-(C₀-C₅ alkyl)-K-(C₁-C₅ alkyl)-, and

(C₃-C₇ cycloalkyl)-(C₀-C₅ alkyl)-K-(C₁-C₅ alkyl)-,

wherein K is -O-, -S(O)_m-, -N(R₂)C(O)-, -C(O)N(R₂)-, -OC(O)-,

-C(O)O-, -CR₂=CR₂- or -C≡C-,

wherein R₂ and the alkyl groups may be further substituted with 1 to 9

halo, -S(O)_mR_{2a}, 1 to 3 of -OR_{2a}, or -C(O)OR_{2a},

and wherein aryl is phenyl or naphthyl, and

heteroaryl is selected from indolyl, thiophenyl, furanyl,

benzothiophenyl, benzofuranyl, pyridinyl, quinolinyl, triazolyl,

imidazolyl, thiazolyl, and benzimidazolyl,

wherein aryl and heteroaryl are unsubstituted or substituted with phenyl,

phenoxy, halophenyl, 1 to 3 of -C₁-C₆ alkyl, 1 to 3 of halo, 1 to 2 of

-OR₂, methylenedioxy, -S(O)_mR₂, 1 to 2 of -CF₃, -OCF₃, nitro,

-N(R₂)(R₂), -N(R₂)C(O)(R₂), -C(O)OR₂, -C(O)N(R₂)(R₂),

-SO₂N(R₂)(R₂), -N(R₂)SO₂-aryl, or -N(R₂)SO₂R₂;

- 76 -

R_{1a} is hydrogen or C₁-C₄ alkyl;

5 R₂ is selected from the group consisting of:
hydrogen, -C₁-C₆ alkyl, -C₃-C₇ cycloalkyl, and -CH₂-phenyl,
wherein the alkyl or the cycloalkyl is unsubstituted or substituted with
hydroxyl, C₁-C₃ alkoxy, thioalkyl, C(O)OR_{2a}, and wherein, if two
-C₁-C₆ alkyl groups are present on one atom, the groups may be
optionally joined to form a C₃-C₈ cyclic ring optionally including
10 oxygen, sulfur, or -NR_{2a}, the C₃-C₈ cyclic ring being selected from the
group consisting of pyrrolidine, piperidine, piperazine, morpholine,
thiomorpholine;

15 R_{2a} is hydrogen or C₁-C₆ alkyl;

R₄ and R₅ are independently selected from the group consisting of:
hydrogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl wherein the
substituents may be 1 to 5 halo, 1 to 3 hydroxy, 1 to 3 C₁-C₁₀
alkanoyloxy, 1 to 3 C₁-C₆ alkoxy, phenyl, phenoxy, 2-furyl, C₁-C₆
20 alkoxycarbonyl, -S(O)_m(C₁-C₆ alkyl);
or wherein R₄ and R₅ may be taken together to form
-(CH₂)_rL_a(CH₂)_s-, wherein L_a is -C(R₂)₂-, -O-, -S(O)_m- or -N(R₂)-,
wherein r and s are independently 1 to 3, and R₂ is as defined above;


25 R₆ and R₈ are independently selected from the group consisting of:
hydrogen, -C₁-C₁₀ alkyl, -(CH₂)_t-aryl, -(CH₂)_qC(O)OR₂,
-(CH₂)_qC(O)N(R₂)(R₂), -(CH₂)_q(C₃-C₆ cycloalkyl),
-(CH₂)_q-K-(C₁-C₆ alkyl), -(CH₂)_q-K-(CH₂)_t-aryl,
-(CH₂)_q-K-(CH₂)_t-(C₃-C₇ cycloalkyl),
30 wherein K is -O-, -S(O)_m-, -CH=CH-, -C≡C-, -N(R₂)C(O)-,
-C(O)NR₂-, -C(O)O-, or -OC(O)-,
wherein the alkyl, -R₂, -(CH₂)_q- and -(CH₂)_t- groups may be
optionally substituted by -C₁-C₄ alkyl, hydroxyl, -C₁-C₄ alkoxy,
carboxyl or carboxylate-C₁-C₄ esters, and

- 77 -

wherein aryl is phenyl, unsubstituted or substituted with 1 to 3 halo, 1 to 3 -OR₂, -C(O)OR₂, 1 to 3 -C₁-C₄ alkyl, -S(O)_mR₂, or 1H-tetrazol-5-yl;

- 5 R₇ and R₉ are independently selected from the group consisting of: hydrogen, -C₁-C₁₀ alkyl, -(CH₂)_t-aryl, wherein aryl is phenyl, unsubstituted or substituted with 1 to 3 halo, 1 to 3 -OR₂, -C(O)OR₂, 1 to 3 -C₁-C₄ alkyl, -S(O)_mR₂, or 1H-tetrazolyl;

10 A is:



- 15 wherein x and y are independently 0, 1, 2 or 3;
Z is -N(R₉)- or -O-, wherein R₉ is hydrogen or C₁-C₆ alkyl;
R₁₀ and R_{10a} are independently selected from the group consisting of: hydrogen, -C₁-C₆ alkyl, trifluoromethyl, phenyl, and substituted C₁-C₆ alkyl wherein the substituents are selected from the
20 group consisting of: imidazolyl, phenyl, indolyl, p-hydroxyphenyl, -OR₂, -S(O)_mR₂, -C(O)OR₂, -C₃-C₇ cycloalkyl, -N(R₂)(R₂), and -C(O)N(R₂)(R₂);
or R₁₀ and R_{10a} may independently be joined to one or both of R₄ and R₅ groups to form alkylene bridges between the terminal nitrogen and the
25 alkyl portion of the R₁₀ or R_{10a} groups, wherein the bridge contains 1 to 5 carbons atoms;

- B is selected from the group consisting of:
phenyl, naphthyl, indolyl, thiophenyl, furanyl, benzothiophenyl,
30 benzofuranyl, pyridinyl, quinolinyl, triazolyl, imidazolyl, thiazolyl, and benzimidazolyl, which is unsubstituted or substituted with one or more substituents selected from the group consisting of:
hydrogen, -C₁-C₆ alkyl, -(CH₂)_t-(C₅-C₆ cycloalkyl),
-(CH₂)_t-aryl, -O-R₂, -O-(CH₂)_t-aryl, -C(O)(CH₂)_t-aryl, cyano, nitro, halo, -(CH₂)_qOR₂, -(CH₂)_qCH(OR₂)R₂,

- 78 -

- 5
10
15
20
- (CH₂)_qCH(OR₂)-(CH₂)_t-aryl,
 - (CH₂)_qC(O)OR₂, -(CH₂)_qC(O)O(CH₂)_t-aryl,
 - (CH₂)_qC(O)O(CH₂)_t-(C₅-C₆ cycloalkyl),
 - (CH₂)_qC(O)N(R₂)(R₂), -(CH₂)_qC(O)N(R₂)(CH₂)_t-aryl,
 - (CH₂)_qC(O)N(R₂)(CH₂)_t-(C₅-C₆ cycloalkyl),
 - (CH₂)_qN(R₂)C(O)(R₂), -(CH₂)_qN(R₂)C(O)(CH₂)_t-aryl,
 - (CH₂)_qN(R₂)C(O)N(R₂)(R₂),
 - (CH₂)_qN(R₂)C(O)N(R₂)(CH₂)_t-aryl,
 - (CH₂)_qN(R₂)C(O)OR₂,
 - (CH₂)_qN(R₂)C(O)O(CH₂)_t-aryl,
 - (CH₂)_qN(R₂)SO₂R₂, -(CH₂)_qN(R₂)SO₂(CH₂)_t-aryl,
 - (CH₂)_qSO₂R₂, -(CH₂)_qSO₂(CH₂)_t-aryl,
 - (CH₂)_qSO₂N(R₂)(R₂), -(CH₂)_qSO₂N(R₂)(CH₂)_t-aryl,
 - (CH₂)_qSO₂N(R₂)C(O)R₂, -(CH₂)_qSO₂N(R₂)C(O)-aryl,
 - (CH₂)_qC(O)NHSO₂R₂, -(CH₂)_q(1H-tetrazol-5-yl),
 - (CH₂)_q(imidazol-2-yl), -(CH₂)_q(1,2,4-triazol-1-yl),
 - (CH₂)_qCONH(1H-tetrazol-5-yl), -(CH₂)_qCONH(imidazol-2-yl), and
 - (CH₂)_qCONH(1,2,4-triazol-1-yl),

wherein aryl is phenyl unsubstituted or substituted with 1 to 2 halo,
amino, 1 to 2 -OR₂, or 1 to 2 -(C₁-C₄ alkyl);

- 25
- m is 0, 1, or 2;
 - n is 1 or 2;
 - q is 0, 1, 2, 3 or 4;
 - t is 0, 1, 2 or 3;

and pharmaceutically acceptable salts and individual diastereomers thereof.

30

- 79 -

2. The compound of Claim 1 wherein:

R₁ is selected from the group consisting of:

C₁-C₁₀ alkyl, aryl(C₁-C₄ alkyl)-,

5 C₅-C₆ cycloalkyl-(C₁-C₄ alkyl)-, (C₁-C₄ alkyl)-K-C₁-C₂ alkyl-,
aryl(C₀-C₂ alkyl)-K-(C₁-C₂ alkyl)-,

C₃-C₆cycloalkyl(C₀-C₂alkyl)-K-(C₁-C₂alkyl)-, wherein K is O or
S(O)_m, and the aryl is phenyl, unsubstituted or substituted by 1 to 2
-C₁-C₄ alkyl, 1 to 2 halo, -OR₂, -C(O)OR₂, -CF₃ or -S(O)_mR₂;

10

R₂ is selected from the group consisting of:

hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, wherein the alkyl or the
cycloalkyl is unsubstituted or substituted with hydroxyl, C₁-C₃ alkoxy,
thioalkyl, C(O)OR_{2a}, and, if two C₁-C₆ alkyls are present on one atom,
15 they may be optionally joined to form a C₅-C₆ cyclic ring optionally
including the heteroatoms oxygen or NR_{2a}, the C₃-C₈ cyclic ring being
selected from the group consisting of pyrrolidine, piperidine, piperazine,
morpholine, thiomorpholine;

20

R_{2a} is hydrogen or C₁-C₄ alkyl;

R₄ and R₅ are independently selected from the group consisting of:

hydrogen, C₁-C₄ alkyl, substituted C₁-C₄ alkyl wherein the substituents
may be 1 to 2 hydroxy or S(O)_m(C₁-C₃alkyl);

25

R₆ and R₈ are independently selected from the group consisting of:

hydrogen, -C₁-C₁₀ alkyl, -(CH₂)_t-aryl, -(CH₂)_qC(O)OR₂,

-(CH₂)_qC(O)N(R₂)(R₂), -(CH₂)_q(C₃-C₆ cycloalkyl),

-(CH₂)_n-K-(C₁-C₆ alkyl), -(CH₂)_n-K-(CH₂)_t-aryl,

30 -(CH₂)_n-K-(CH₂)_t-(C₃-C₇ cycloalkyl), wherein K is -O-, -S(O)_m-,
-N(R₂)C(O)-, -C(O)NR₂-, -C(O)O-, or -OC(O)-,


wherein the alkyl, -R₂, -(CH₂)_q- and -(CH₂)_t- groups may be
optionally substituted by -C₁-C₄ alkyl, hydroxyl, -C₁-C₄ alkoxy,
carboxyl or carboxylate-C₁-C₄ esters, and

- 80 -

wherein aryl is phenyl, unsubstituted or substituted with 1 to 3 halo, 1 to 3 -OR₂, -C(O)OR₂, 1 to 3 -C₁-C₄ alkyl, -S(O)_mR₂, or 1H-tetrazolyl;

- 5 R₇ and R₉ are independently selected from the group consisting of: hydrogen, -C₁-C₁₀ alkyl, -(CH₂)_t-aryl, wherein the aryl group may be optionally substituted with 1 to 3 halo, 1 to 3 -OR₂, -C(O)OR₂, 1 to 3 -C₁-C₄ alkyl, -S(O)_mR₂ or 1H-tetrazol-5-yl;

10 A is:



15

wherein x is 0 or 1;

- R₁₀ and R_{10a} are independently selected from the group consisting of: hydrogen, and C₁-C₃ alkyl; or R₁₀ and R_{10a} can independently be joined to one or both of the R₄ and R₅ groups to form alkylene bridges
 20 between the terminal nitrogen and the alkyl portion of the R₁₀ or R_{10a} groups to form 5 or 6 membered rings containing the terminal nitrogen;

- B is selected from the group consisting of:
 phenyl, indolyl, pyridinyl, and pyrimidinyl, unsubstituted or
 25 substituted with one or more substituents selected from the group consisting of:

- hydrogen, -C₁-C₆ alkyl, -(CH₂)_t-(C₅-C₆ cycloalkyl),
 -(CH₂)_t-aryl, -O-R₂, -O-(CH₂)_t-aryl, -C(O)(CH₂)_t-aryl, cyano, nitro,
 halo, -(CH₂)_qOR₂, -(CH₂)_qCH(OR₂)R₂,
 30 -(CH₂)_qCH(OR₂)-(CH₂)_t-aryl,
 -(CH₂)_qC(O)OR₂, -(CH₂)_qC(O)O(CH₂)_t-aryl,
 -(CH₂)_qC(O)O(CH₂)_t-(C₅-C₆ cycloalkyl),
 -(CH₂)_qC(O)N(R₂)(R₂), -(CH₂)_qC(O)N(R₂)(CH₂)_t-aryl,
 -(CH₂)_qC(O)N(R₂)(CH₂)_t-(C₅-C₆ cycloalkyl),
 -(CH₂)_qN(R₂)C(O)(R₂), -(CH₂)_qN(R₂)C(O)(CH₂)_t-aryl,

- 81 -

- $(\text{CH}_2)_q\text{N}(\text{R}_2)\text{C}(\text{O})\text{N}(\text{R}_2)(\text{R}_2)$,
- $(\text{CH}_2)_q\text{N}(\text{R}_2)\text{C}(\text{O})\text{N}(\text{R}_2)(\text{CH}_2)_t\text{-aryl}$,
- $(\text{CH}_2)_q\text{N}(\text{R}_2)\text{C}(\text{O})\text{OR}_2$,
- $(\text{CH}_2)_q\text{N}(\text{R}_2)\text{C}(\text{O})\text{O}(\text{CH}_2)_t\text{-aryl}$,
5 - $(\text{CH}_2)_q\text{N}(\text{R}_2)\text{SO}_2\text{R}_2$, - $(\text{CH}_2)_q\text{N}(\text{R}_2)\text{SO}_2(\text{CH}_2)_t\text{-aryl}$,
- $(\text{CH}_2)_q\text{SO}_2\text{R}_2$, - $(\text{CH}_2)_q\text{SO}_2(\text{CH}_2)_t\text{-aryl}$,
- $(\text{CH}_2)_q\text{SO}_2\text{N}(\text{R}_2)(\text{R}_2)$, - $(\text{CH}_2)_q\text{SO}_2\text{N}(\text{R}_2)(\text{CH}_2)_t\text{-aryl}$,
- $(\text{CH}_2)_q\text{SO}_2\text{N}(\text{R}_2)\text{C}(\text{O})\text{R}_2$, - $(\text{CH}_2)_q\text{SO}_2\text{N}(\text{R}_2)\text{C}(\text{O})\text{-aryl}$,
- $(\text{CH}_2)_q\text{C}(\text{O})\text{NHSO}_2\text{R}_2$, - $(\text{CH}_2)_q(1\text{H-tetrazol-5-yl})$,
10 - $(\text{CH}_2)_q(\text{imidazol-2-yl})$, - $(\text{CH}_2)_q(1,2,4\text{-triazol-1-yl})$,
- $(\text{CH}_2)_q\text{CONH}(1\text{H-tetrazol-5-yl})$, - $(\text{CH}_2)_q\text{CONH}(\text{imidazol-2-yl})$, and
- $(\text{CH}_2)_q\text{CONH}(1,2,4\text{-triazol-1-yl})$,

wherein aryl is phenyl, unsubstituted or substituted with 1 to 2 halo,
15 amino, 1 to 2 $-\text{OR}_2$, or 1 to 2 $-(\text{C}_1\text{-C}_4\text{ alkyl})$,

m is 0, 1 or 2;

n is 1 or 2;

q is 0, 1, 2 or 3;

20 t is 0, 1, 2 or 3;



and pharmaceutically acceptable salts and individual diastereomers
thereof.

25

30

- 82 -

3. A compound of the formula:

wherein R₁ is selected from the group consisting of:

30 B is phenyl unsubstituted or substituted with one or more substituents selected from the group consisting of:

hydrogen,

-(CH₂)_t-aryl, C₁-C₃ alkyl, -(CH₂)_qOR₂,-(CH₂)_qC(O)OR₂, -(CH₂)_qC(O)O(CH₂)_t-aryl,-(CH₂)_qC(O)N(R₂)(R₂), -(CH₂)_qC(O)N(R₂)(R₂),-(CH₂)_qC(O)N(R₂)(CH₂)_t-aryl,

- 83 -

- (CH₂)_qN(R₂)C(O)(R₂), -(CH₂)_qN(R₂)C(O)N(R₂)(R₂),
-(CH₂)_qN(R₂)C(O)OR₂,
-(CH₂)_qN(R₂)SO₂R₂, -(CH₂)_qN(R₂)SO₂(CH₂)_t-aryl,
-(CH₂)_qSO₂R₂, -(CH₂)_qSO₂(CH₂)_t-aryl,
5 -(CH₂)_qSO₂N(R₂)(R₂), -(CH₂)_qSO₂N(R₂)(CH₂)_t-aryl,
-(CH₂)_qSO₂N(R₂)C(O)R₂, -(CH₂)_qSO₂N(R₂)C(O)-aryl,
-(CH₂)_qC(O)NHSO₂R₂, -(CH₂)_q(1H-tetrazol-5-yl),
-(CH₂)_q(imidazol-2-yl), -(CH₂)_q(1,2,4-triazol-1-yl),
-(CH₂)_qCONH(1H-tetrazol-5-yl), -(CH₂)_qCONH(imidazol-2-yl), and
10 -(CH₂)_qCONH(1,2,4-triazol-1-yl),

wherein aryl is phenyl unsubstituted or substituted with 1 to 2 halo,
amino, 1 to 2 -OR₂, or 1 to 2 -(C₁-C₄ alkyl);

R₂ is selected from the group consisting of:
15 hydrogen, -C₁-C₆ alkyl, -C₃-C₇ cycloalkyl, and -CH₂-phenyl, optionally
substituted with hydroxyl, C₁-C₃-alkoxy, thiomethyl, -C(O)OR_{2a},
wherein if two -C₁-C₆ alkyl groups are present on one atom, the groups
may be optionally joined to form a C₃-C₄ cyclic ring optionally
including oxygen, sulfur or -NR_{2a};
20

R_{2a} is hydrogen or C₁-C₆ alkyl;

q is 0, 1, 2 or 3;


25 t is 0, 1, or 2;

and pharmaceutically acceptable salts and individual diastereomers
thereof.

30

- 84 -

4. The stereospecific compound of Claim 1 which is:




wherein R₁, R_{1a}, R₄, R₅, R₆, R₇, R₈, R₉, A and B are as defined in Claim 1.

- 85 -


5. A compound which is selected from the group consisting of:

5




10

15




20

25






30




- 86 -






- 87 -





- 88 -



- 89 -



- 90 -



and pharmaceutically acceptable salts thereof.

25



30

- 91 -

6. A process for the preparation of a compound of Claim 1 which comprises reacting a compound of the formula:



with a compound of the formula




wherein R₁, R_{1a}, R₄, R₅, R₆, R₇, R₈, R₉, A and B are as defined in Claim 1 and L is a protecting group which is subsequently removed if present and salts are formed if desired.


30

- 92 -


7. A process for the preparation of a compound of Claim 1 which comprises reacting a compound of the formula:



with a compound of the formula



to give compound of formula



wherein R₁, R_{1a}, R₄, R₅, R₆, R₇, R₈, R₉, A and B are as defined in Claim 1 and L is a protecting group which is subsequently removed if present and salts are formed if desired.

8. A composition useful for increasing the endogenous production or release of growth hormone in a human or an animal which comprises an inert carrier and an effective amount of a compound of Claim 1.

- 93 -

9. A composition useful for increasing the endogenous production or release of growth hormone in a human or an animal which comprises an inert carrier and an effective amount of
5 a compound of Claim 1 in combination with an additional growth hormone secretagogue.

10. The composition of Claim 9 wherein the additional growth hormone secretagogue is selected from the group consisting of:
10 of: growth hormone releasing peptide GHRP-6; growth hormone releasing peptide GHRP-2; growth hormone releasing peptide GHRP-1; B-HT920; growth hormone releasing factor; an analog of growth hormone releasing factor; IGF-1 and IGF-2.

11. A composition useful for the treatment of osteoporosis which comprises a combination of a bisphosphonate compound and a
15 compound of Claim 1.

12. The composition of Claim 11 wherein the
20 bisphosphonate compound is alendronate.

13. A method for increasing levels of endogenous growth hormone in a human or an animal which comprises
25 administering to such human or animal an effective amount of a compound of Claim 1.

14. A method for the treatment of osteoporosis which comprises administering to a patient with osteoporosis a combination of a
30 bisphosphonate compound and a compound of Claim 1.

15. The method of Claim 14 wherein the bisphosphonate compound is alendronate.

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US95/07001

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : Please See Extra Sheet. US CL : 514/12, 21, 19, 255, 253, 235.8; 544/121, 373, 386, 366 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/12, 21, 19, 255, 253, 235.8; 544/121, 373, 386, 366 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS search terms: piperazine, growth hormone				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	US, A, 5,317,017 (OK ET AL.) 31 May 1994.	1-15		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td> * Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *&* document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *&* document member of the same patent family
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *&* document member of the same patent family			
Date of the actual completion of the international search 04 AUGUST 1995		Date of mailing of the international search report 05 SEP 1995		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer SHEELA J. HUFF <i>Nathan Tepper</i> Telephone No. (703) 308-0196		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/07001

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 38/00, 31/495, 31/50, 31/535; A01N 43/58, 43/60; C07D 415/00, 417/00, 403/00, 241/04, 295/00